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Abstract 
 
Inflammatory bowel diseases (IBD) and cancers of the gastrointestinal (GI) tract cauce 
considerable morbidity and mortality in the Western world. There is a need to understand 
more profoundly the biology of these diseases in order to enhance their diagnostics and 
therapeutic measures. It is imperative to define and validate cellular targets and biomarkers, 
so that subgroups of patients that are likely to respond to the treatments can be identified. The 
current study concentrates on a novel potential biomarker. Its significance for the biology of 
the normal GI tract, the IBDs, the cancers of the GI tract and neuroendocrine tumors (NET) is 
studied. 
IBD cDNA expression libraries were screened for genes with restricted expression 
patterns to detect potential diagnostic, prognostic or predictive markers and/or potential 
targets for therapeutic intervention. A previously unknown gene, later named Reg IV, was 
identified. The predicted novel gene was cloned and expressed in mammalian cells, and 
eventually also mapped at both RNA and protein level ex vivo in human tissues to confirm the 
detection of a novel, naturally expressed protein. The gene was selected for further 
characterization because of its restricted expression pattern and its upregulated expression in 
IBDs and in colorectal cancer (CRC).  
 DNA cloning techniques, Western, Southern, and Northern blot techniques, cell 
culture, gene transfection, in situ hybridization, immunohistochemistry, and 
immunofluorescence were used to characterize the newly discovered gene and its protein 
product. 
Reg IV protein is a 17 kD secreted C-type lectin that belongs to the Reg protein 
family of known mitogens and/or antiapoptotic factors. A detailed immunohistochemical 
analysis indicated that it is physiologically expressed in enteroendocrine cells (EEC) and in 
proliferating goblet cells. It is expressed to a lesser extent in pancreas, stomach, prostate and 
testes. In EECs, it is co-expressed with serotonin and substance P, and partially co-expressed 
with somatostatin, ghrelin, PYY, GLP-1, GLP-2, and secretin. Interestingly, co-expression 
with somatostatin and ghrelin occurs only in colon and appendix, but not in the small 
intestine, which suggests that the EECs of the small intestine and colon have different 
functions.  
An upregulated expression of Reg IV protein was found in the intestinal epithelium 
during inflammation and regeneration, so it can be considered a marker of “reactive”, 
proliferating goblet cells. This upregulated expression was found in goblet cells of intestinal 
metaplasia, in proliferating margins of stomach ulcers, and in IBDs.  
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Reg IV expression was also upregulated in many mucinous and neuroendocrine 
tumors (NET). Strong expression was noted in mucinous cystadenoma of the appendix and 
pseudomyxoma peritonei. Reg IV expression in these tumors coincided partially with CDX2, 
MUC2, MUC5AC, and MUC6, but no regulatory correlation was found. Reg IV was also 
upregulated in NETs of small intestine, appendix, colon, lung (small cell lung cancer), 
parathyroid, skin (Merkel’s carcinoma), and, more rarely, of pancreas. Thus, in NETs, the 
expression was not restricted to the GI NETs. Co-expression with the intestinal transcription 
factor Hath1 was studied in normal gut epithelium and in the NETs, but no regulatory 
correlation was found. In ileal NET, a spatial correlation in with CD138, c-met, bFGF and 
HGF was found, supporting the existing data on the role of Reg IV in EGFR signaling and 
cell proliferation.  
Reg IV was thus found to be a novel member of the Reg protein family that is an 
intestinal protein and a putative mitogen. The regulation of its expression and its exact 
mechanisms of action still remain to be elucidated. Based on its expression pattern, Reg IV 
might have a role in maintaining the integrity of the epithelial lining of the gastrointestinal 
(GI) tract, in the proliferation of gut goblet cells, and in the development of certain types of 
GI cancer, i.e., CRC, PMP and NETs. Further investigation is needed to confirm its value as a 
therapeutic target and/or prognostic or predictive biomarker. 
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Abbreviations 
 
5HT   serotonin 
AP-1   activator protein 1 
bFGF   basic fibroblast growth factor 
bHLH   basic helix-loop-helix 
CD   Crohn’s disease 
cDNA   complementary deoxyribonucleic acid 
CDX2   caudal type homeo box transcription factor 2 
CgA   chromogranin A 
CTLD   C-type lectin domain 
CRC   colorectal cancer 
CRD   carbohydrate recognition domain 
DNA   deoxyribonucleic acid 
DTT   dithiothreitol 
EEC   enteroendocrine cell 
EGF   epidermal growth factor 
EGFR   epidermal growth factor receptor 
FISH   fluorescence in situ hybridization 
FITC  fluorescein isothiocyanate 
GI   gastrointestinal 
GLI1   glioma-associated oncogene homolog 1  
GLP   glucagon-like peptide 
GPCR   G-protein coupled receptor 
Hath1   atonal homolog 1 
HER-4  v-erb-a erythroblastic leukemia viral oncogene homolog 4 
HGF   hepatocyte growth factor 
HIP/PAP  gene expressed in hepatocellular carcinoma-intestine-pancreas/pancreatitis-
associated protein 
IBD  inflammatory bowel disease 
IL   interleukin 
INGAP  islet neogenesis-associated protein 
IPMN   intraductal papillary mucinous neoplasms of the pancreas 
MAP   mitogen-activated protein 
mRNA   messenger RNA 
MUC2   mucin 2 
MUC5AC  mucin 5AC 
MUC6   mucin 6 
NET   neuroendocrine tumor 
NOD   non-obese diabetic 
PAC  plasmid artificial chromosome 
PAP   pancreatitis-associated protein 
PCR   polymerase chain reaction 
PI3K   phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKA   protein kinase A 
PKC   protein kinase C 
PMP   pseudomyxoma peritonei 
PSP   pancreatic stone protein 
PTP  pancreatic thread protein  
PYY   peptide YY 
Reg  regenerating protein 
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RELP  reg-like protein (Reg IV) 
RNA   ribonucleic acid 
RT-PCR  reverse transcription polymerase chain reaction 
SCLC   small cell lung cancer 
SDS-PAGE sodium dodecyl sulfate polyacrylamide gel electrophoresis  
SSTR5   somatostatin receptor type 5  
SuP   substance P 
TNF-α   tumor necrosis factor α 
TGF-β   transforming growth factor β 
TRITC  tetramethylrhodamine isothiocyanate 
UC   ulcerative colitis 
VEGF  vascular endothelial growh factor 
WHO   World Health Organization 
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1. Introduction 
 
 
Immune system-related chronic diseases are an increasingly prevalent cause of morbidity and 
mortality in all parts of the world. Inflammatory bowel disease (IBD) is more common in 
developed countries, and the incidence seems to be increasing, or at least stable, all over the 
world (Molodecky et al., 2012, Lakatos, 2006). In addition to chronic morbidity, patients with 
long-standing IBD have an increased risk of developing colorectal cancer (CRC) (Herrinton 
et al., 2012). The bacterial flora and the cytokine profile of the inflamed epithelium seem to 
be associated with the carcinogenesis (Yang et Pei, 2006, Popinova et al., 2008), suggesting a 
connection between inflammation and cancer.  
The focus of cancer treatment is moving slowly from cytotoxic regimens and 
irradiation towards targeted drugs focusing on specified proteins. The development is also 
shifting towards individualized cancer care, which must be based on a detailed understanding 
of the biology of the cancer cells and the tumor microenvironment. (Hanash et al., 2011, 
Wistuba et al., 2011.) It is anticipated that basic reseach will support this development, and 
that the definition of new prognostic and predictive cancer markers, and drug targets will be 
facilitated.  
The novel targeted cancer treatments rely on such target proteins. These proteins 
display upregulated expression in cancer and a restricted expression profile in physiological 
conditions. They could thus be potentially be targeted with antibodies or small molecular 
drugs that block their function or inhibit their expression, without disrubting healthy tissues. 
In search for potential drug targets, gene expression libraries of the normal gut, 
inflammatory bowel disease (IBD), and colonic cancer were studied by in silico mining. A 
novel sequence was found, which potentially represents a new gene upregulated in 
inflammation and cancer. Its expression profile in the normal human body seemed restricted, 
thus showing potential as a feasible target protein. The structure of the novel gene resembled 
that of the previously characterized Reg family genes, known to be associated with 
inflammation, regeneration, and cell proliferation. However, the newly discovered sequence 
was located on chromosome 1, while the other Reg genes are clustered on chromosome 2. 
Also, the sequence homology between Reg IV and the previously characterized Reg genes is 
lower than the homology between other Reg genes. Thus, Reg IV’s different localization in 
the genome and its lower sequence homology suggests that it is a more distant member of the 
Reg gene family. The protein product of the gene was thus expected to have properties that 
partly differ from the previously characterized Reg proteins. To gain information on the 
biology of the IBDs and the cancer of the GI-tract, this gene and its product were chosen for 
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further characterization, with the aim to improve the treatment of these diseases, and as a 
potential therapeutic target and/or biomarker in IBD and CRC. 
 13 
2. Review of the literature 
 
 
2.1 Inflammatory bowel diseases (IBD) 
 
Inflammatory bowel diseases (IBD) are chronic inflammatory disorders of the gastrointestinal 
tract with multifactorial etiology. The two main forms of the disease are Crohn’s disease 
(CD), which may affect both the small and the large intestine in a patch-like manner, and 
ulcerative colitis (UC), which affects only the colorectum and generally presents a more 
diffuse inflammation of the bowel mucosa. The histological features of the diseases differ 
somewhat: CD is characterized by thickened submucosa, transmural inflammation and 
ulcerations, and non-caseating granulomas, whereas UC more often presents with more 
superficial inflammation limited to mucosa and submucosa and crypt abscesses. (Khor et al., 
2011.) The worldwide incidence of these diseases is increasing: UC is estimated to affect 
between 0.5–24.5/100,000 persons, and CD between 0.1–16/100,000 persons (Lakatos, 
2006). 
The pathophysiological mechanisms of the diseases are similar, but disease-specific 
genetical and environmental risk factors also exist (Podolsky, 2002, Khor et al., 2011). 
Heritability studies have revealed a genetic background for the diseases (Tysk et al., 1988, 
Orholm et al., 1991), as have genome-wide analyses that map potential susceptibility genes 
(Franke et al., 2010, Anderson et al., 2011). Susceptibility genes of IBDs include genes 
involved in the regulation of lymphocyte activation, innate defense, gut barrier function, 
reactive oxygen species neutralization, inflammation mediation, mucosal restitution, and 
others; each mutated or multiplied gene has been found only in a very small proportion of 
IBD patients (Khor et al., 2011).  Furthermore, the concordance rate in monozygotic twins is 
only 10-15% in UC and 30-35% in CD, suggesting that environmental factors have a 
substantial role in the pathogenesis (Spehlmann et al., 2008). One important environmental 
factor is the luminal flora, i.e., its presence per se and its constitution, as demonstrated by 
studies on colitis-susceptible rat strains grown in germ-free conditions and thereafter 
colonized (Rath et al., 2001), and by studies on IBD patients treated with antibiotics or with 
normal commensal bacteria (Gionchetti et al., 2006, Sutherland et al., 1991). The immune 
characteristics of the patient, including T-cell, B-cell, dendritic cell and macrophage functions 
and innate immunity responses, as well as mucosal factors, including the integrity of the 
mucosal epithelium and the constitution of the mucus layer, also play an important role in the 
pathogenesis of the disease (for a review, see Podolsky, 2002, Khor et al., 2011). 
Interestingly, early appendectomy may reduce the risk of UC (Andersson et al., 2001). 
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 IBDs are diagnosed mainly by clinical, endoscopic and histological means. The 
disease markers used are non-specific, so more accurate markers are needed for the diagnosis 
and follow-up (Mendoza and Abreu, 2009). Furthermore, the chronic inflammation of the gut 
mucosa in IBDs is a known risk factor for colorectal carcinoma (Eaden et al., 2001, Jess et al., 
2005, Baars et al., 2012). More detailed information on the biology of IBDs is therefore 
needed. 
 
 
2.2 Mucinous cystadenoma of the appendix and pseudomyxoma peritonei (PMP) 
 
The appendiceal mucinous cystadenomas (previously called mucocele) and pseudomyxoma 
peritonei (PMP) are characterized by abundant overgrowth of mucus-secreting goblet cells. 
The appendiceal mucinous cystadenoma is restricted to the appendix and its adjacent 
surroundings, whereas PMP is a disease of the peritoneal cavity. PMP is a rare tumor, 
representing only about 1% of colorectal cancers (Choudry et al., 2012). Even though their 
cell morphology is often well differentiated, the diseases show neoplastic characteristics. 
Their potential of recurrence is predicted by the extent of invasion in the appendix and/or to 
the peritoneal cavity (Panarelli and Yantiss, 2011). Pseudomyxoma peritonei is, in fact, a 
general term for a group of diseases which are characterized by the accumulation of mucinous 
ascites in the peritoneal cavity. Usually PMP presents with malignant mucus-producing 
epithelial islets, but the term can be used to describe an acellular mucinous ascites as well. 
(Panarelli and Yantiss, 2011.) The origin of this mucus-producing epithelium used to be 
unclear, but now it is thought that most cases of pseudomyxoma peritonei originate from the 
appendix, although in rare cases the malignant epithelium can originate from the ovaries or 
the omentum (Panarelli and Yantiss, 2011). According to the 2010 WHO classification of 
appendiceal mucinous neoplasms and pseudomyxoma peritonei, tumors confined to the 
appendix are regarded as adenomas as long as they do not have neoplastic epithelium in the 
appendix wall (in which case the classification is “uncertain malignant potential”). Tumors 
beyond the appendix are divided into low-grade mucinous adenocarcinoma (low-grade 
epithelium in peritoneal mucin) and into high-grade mucinous adenocarcinoma (high-grade 
epithelium in peritoneal mucin). 
 The treatment options of PMP include surgery and/or chemotherapy. If the tumor can 
be macroscopically completely removed, 5-year survival of the patients is generally good 
(94% in a recent Swedish study), but poorer, if there is a residual tumor (28%) (Andréasson et 
al., 2012). PMP is essentially a disease of MUC2-producing goblet cells (O’Connell et al., 
2002) and thus, its biology probably differs drastically from non-mucinous malignancies of 
the GI tract (Choudry et al., 2012). Choudry et al. (2012) hypothesize that investigation of the 
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pathways leading to this phenotype will help to generate a specific treatment for this disease. 
For evident reasons, mucins, mucin-related pathways and specifically MUC2 has been 
considered a therapeutic target by the authors, as mucin accumulation is one of the most 
important causes of the morbidity of this disease. 
 
 
2.3 Neuroendocrine tumors (NET) 
 
Neuroendocrine tumors (NET) are a heterogeneous group of neoplasms that originate from 
the neuroendocrine cells of different organs. Neuroendocrine cells generally have uniform 
nuclei and a granular or faintly staining cytoplasm, but the diagnosis of NETs is based on the 
detection of cellular markers, such as chromogranin A, synaptophysin, and neuron-specific 
enolase (Klöppel, 2007). The NETs have been considered a rare disease, but their incidence 
and prevalence has been rising over the past decades (Frilling et al., 2012, Yao et al., 2008, 
Modlin et al., 2003). The estimated incidence in the USA has increased from 1.09/100,000 in 
1973 to 5.25/100,000 in 2004, which is a nearly 5-fold increase (Yao et al., 2008). The most 
common sites of origin are the GI-tract (58% of NETs in 2004 in the USA) and the lung 
(27%) (Yao et al., 2008). An older series showed similar results: 67,5% of NETs originated 
from the GI-tract, out of which 41,8% in the small intestine, 27,4% in the rectum, and 8,7% in 
the stomach, and 25,3% from the broncopulmonary system (Modlin et al., 2003).  
 The heterogeneity of the NETs is reflected in the varying survival data on the 
patients. NETs have been traditionally considered an indolent type of cancer, but as the five-
year survival of any type of NETs was 67.2% in the study of Modlin et al. (2003), and as 
there is great variability among different NETs, the authors question this assumption of 
general indolence. Local disease and low-grade tumors have the best prognosis (Yao et al., 
2008). Ki-67% is the most important grading tool (Frilling et al., 2012, Remes et al., 2012). 
The primary tumor site also affects the prognosis; among gastrointestinal NETs, appendiceal 
tumors tend to have a good prognosis (median survival of 360 months in a localized disease), 
jejunal/ileal intermediate (111 months), and liver tumors have the poorest prognosis (50 
months) (Yao et al., 2008).  
The tumors are often symptomless in the beginning and thus late diagnosed. From the 
treatment point of view, a late diagnosis is a problem. To date, the only curative treatment is 
surgery, which often is not feasible because the tumors tend to metastasize early (Frilling et 
al., 2012, Modlin, 2003). Chemotherapy is often of little benefit, although new combinations 
may be efficient in selected patient groups (Frilling et al., 2012, Strosberg et al., 2011). For 
the NETs of the GI tract, somatostatin analogues may stabilize the disease (Frilling et al., 
2012, Naraev et al., 2012). Recently, new targeted therapies of the VEGFR or mammalian 
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target of rapamycin (mTOR) pathways have shown promising results in the treatment of 
pancreatic NETs (Frilling et al., 2012, Naraev et al., 2012, Teulé and Casanovas, 2012). 
Several potential molecular targets have been reported in NETs. EGFR and HER-4 
are expressed in most NETs (Srirajaskanthan et al., 2010). NETs frequently show activation 
of the EGFR pathway downstream targets Akt and ERK1/2 (Shah et al., 2006). mTOR, which 
is activated via PI3K-Akt pathway, is expressed in 61% of gastrointestinal NETs, more often 
in foregut tumors and in metastatic disease (Kasajima et al., 2011). Also insulin-like growth 
factor-1 signaling has been reported as a mechanism of action in the proliferation of the 
neuroendocrine cell line BON (von Wichert et al., 2000). Welin et al. (2006) have reported 
the expression of functional PDGF receptors in midgut NETs. What is more, NETs are highly 
vascularized, and especially midgut tumors show high expression of VEGF (Terris et al., 
1998). These and other findings have led to trials with several targeted molecular drugs, but 
new targets, drugs and drug combinations are still needed to fight these diseases effectively 
(Frilling et al., 2012, Teulé and Casanovas, 2012, Naraev et al., 2012). 
 
 
2.4 The Reg protein family 
 
In 1988, Terazono et al. isolated a novel gene sequence from regenerating rat pancreatic 
islets, encoding a 165 amino acid protein with a predicted 21 amino acid signal peptide and a 
C-type lectin domain. Since the gene was selectively expressed in hyperplastic and 
regenerating islets, it was named “Regenerating gene” or “Reg”. A human pancreas-derived 
cDNA library was found to contain a homologue of the rat Reg gene. It encoded for a 166 
amino acid preprotein with a 22 amino acid signaling sequence, very similar to the previously 
found rat Reg protein (Watanabe et al., 1990). This gene was later shown to code for the 
previously characterized pancreatic stone protein (De Caro et al., 1979) and the partially 
determined pancreatic thread protein (Gross 1985). The rat Reg protein was subsequently 
named Reg 1, and the human homologue Reg 1α, in order to differentiate from homologous 
genes discovered later in mice and in humans. 
Since then, a total of 19 Reg proteins have been described in mammals, including five 
human family members. After the discovery of other proteins with the same characteristics, 
they were grouped into a multigene superfamily, which carried the name Reg. Unno et al. 
(1993) proposed a division into three major groups, based on the primary and secondary 
structure of the Reg proteins. In 2001, due to the identification of Reg IV (Hartupee et al., 
2001, I), the number of subcategories was extended into four. 
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Figure 1. The different Reg proteins and their phylogenetic relations. Modified from Laurine et 
al., 2005. 
 
 
The Reg proteins are small, secreted C-type lectins. They contain a typical calcium-dependent 
carbohydrate recognition domain (CTLD), including four conserved cysteins that form two 
disulphide bridges (S1 and S2), and seven additional structurally important highly conserved 
amino acids. However, unlike the CTLD found in the calcium-dependent animal lectin 
superfamily, Reg proteins have a third disulphide bridge (S3) close to the N terminus 
(Bertrand et al., 1996). The secondary structure of Reg IV protein is presented in Figure 2. 
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Figure 2. Secondary structure of the Reg IV protein. Signal sequence is shown in dark grey 
and the mature protein in light grey and white. The cystein residues and disulphide bonds are 
shown schematically. Created using the 
http://www.nextprot.org/db/entry/NX_Q9BYZ8/sequence software. 
 
The shared chromosomal localization of the Reg genes (for types I and III on chromosome 
2p12 in human, for types I, II and III on 6C in mouse), their tandem clustering in the genome, 
and the similarity in their intron-exon organization suggest that they are derived by 
duplication from a common ancestor gene. Reg IV, however, is located in the human 
chromosome 1, suggesting a more distant relationship. 
The group I Reg proteins in humans are Reg 1α (lithostatin, PSP, PTP) and Reg 1β, 
the group II has no human genes, group III proteins are HIP/PAP (gene expressed in 
hepatocellular carcinoma-intestine-pancreas/gene encoding pancreatitis-associated protein; 
also called Reg 3β, Reg3 A, Reg-2, PAP 1 and PTP) and Reg IIIγ (Reg III, Reg 3gamma, 
PAP 1B, PAP II, PAP III), while group IV contains only one protein, Reg IV (RELP) (Unno 
et al., 1993, I, NCBI Gene Database). The biological functions of this group of proteins are 
multiple, often associated with inflammation and cell proliferation, and partially shared, while 
each protein has its particular expression profile in various different organs and cells. Even 
though Reg proteins are lectins, they seem to have several biological functions that are not 
necessarily related to binding carbohydrates. The proteins can possibly take each other’s 
functions, as double negative knock-out mouse experiments have lead to apparently normal 
phenotypes (Unno et al., 2002). Moreover, the plethora of mouse and rat orthologues for the 
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human proteins leads to difficulties in interpreting the data acquired from animal experiments. 
Here the different members of the human Reg protein family are discussed in detail. 
 
 
2.4.1 Reg Iα  
 
The Reg gene, later Reg Iα, was first published by Terazono et al. in 1988. However, 
the protein encoded by the gene had already been characterized in 1979 under the name of 
pancreatic stone protein (PSP) (De Caro et al. 1979), and a partial sequence of the same gene 
was defined in 1985, with the pancreatic thread protein (PTP) as the peptide product. It is 
physiologically expressed in pancreas, gastric mucosa, kidney (Watanabe et al., 1990), gall 
bladder (Unno et al., 1993), in Paneth cells of duodenum and in non-mature, multipotent 
columnar cells of the gut (Senegas-Balas et al., 1991). According to Zenilman et al. (1997), it 
is not expressed in normal colonic mucosa. Sekikawa et al. (2005a), however, reported 
expression of Reg Iα in a few colonic epithelial cells, situated on the crypts. The authors did 
not specify the nature of these cells. In normal, non-proliferating pancreas, Reg Iα is 
expressed in acinar cells and not in islets, while in regenerating pancreas, the regenerating 
islets express the protein (Kimura et al., 1992, Rouquiert et al., 1991, Unno et al., 1993, 
Okamoto 1999, Watanabe et al., 1994).  
Reg Iα was reported to inhibit the formation of calcium carbonate crystals in 
pancreatic fluid (Bernard JP et al. 1992, Geider S 1996), although this function was later 
questioned (Bimmler et al. 1997, De Reggi et al. 1998). In fact, Reg Iα can form insoluble, 
fibrillar, helix-shaped, and protease-resistant structures (Graf et al., 2001), and it is a major 
component of pancreatic stones and of the organ matrix causing occlusion of pancreatic stents 
(De Caro et al., 1979, Bockman et al., 1986, Farnbacher et al., 2005). The plaque-forming 
tendency of this protein is further supported by the fact that Reg Iα and HIP/PAP are also 
associated with the formation of cerebral plaques in Alzheimer's disease, possibly via a 
general inflammation process (Duplan et al., 2001). 
Reg Iα is overexpressed in acute pancreatitis (Rouquier et al., 1991, Schmiegel et al., 
1990, Satomura et al., 1995) and in inflammatory bowel diseases (IBD) (Lawrance et al. 
2001, Dieckgraefe et al., 2002, Sekikawa et al. 2005a, Granlund et al., 2011). A role in the 
aggregation of bacteria has been proposed (Iovanna et al., 1993). Reg Iα has also been linked 
to infection in general, as it is upregulated during sepsis, and activates neutrophils (Keel et al., 
2009).  
Reg Iα functions as a pancreatic beta-cell growth factor (Levine et al., 2000, 
Okamoto, 1999, Unno et al., 2002, Watanabe et al., 1994). It was associated with 
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amelioration of diabetes in animal models, and it functions possibly in an autocrine manner 
(Okamoto, 1999, Unno et al., 2002, Watanabe et al., 1994). Okamoto’s group’s Reg Iα 
transgenic mice that expressed Reg Iα in pancreatic β-cells were healthy and did not develop 
tumors (Unno et al, 2002), whereas the transgenic Reg Iα mice generated by Yamaoka and 
colleagues developed multiple tumors, and the islet cells that overexpressed Reg1α were 
apoptotic, leading to diabetes (Yamaoka et al., 2000). A Reg Iα-/- gene knock-out mouse 
model has also been created. These mice grew and reproduced normally, but when their 
pancreatic islets were pharmacologically induced to proliferate, the islets of Reg Iα-/- mice 
proliferated less than those of the control mice (Okamoto, 1999, Unno et al., 2002). Reg Iα 
has been shown to be mitogenic to pancreatic ductal cells, too (Zenilman et al., 1998). 
Autoantibodies to Reg Iα have been reported in Type I and Type II diabetes (Shervani et al. 
2004). Thus, Reg Iα has a role in diabetes, but its use as a drug is compromised by possible 
severe side effects. 
Furthermore, increased serum concentrations of Reg Iα have been observed in several 
gastrointestinal cancers, and, surprisingly, in renal failure (Satomura et al., 1995). Zhou et al. 
(2010) reported that Reg Iα expression was more frequent in pancreatic cancer patients with 
diabetes than without diabetes. Reg Iα was expressed in actively proliferating colorectal cell 
lines (Bernard-Perrone et al., 1999) and in colon mucosa at the transition zone of colorectal 
cancer, indicating a possible role as a marker for mucosa in risk for developing a cancer 
(Zenilman et al., 1997). It is overexpressed in colorectal cancer (Astrosini et al., 2008, 
Macadam et al., 2000, Rechreche et al., 1999, Sekikawa et al., 2005a, Watanabe et al., 1990), 
in stomach cancer (Sekikawa et al., 2005b, Watanabe et al., 1990), in cholangiocarcinoma 
and its precursor lesions (Harada et al., 2001), in hepatocellular cancer (Yuan et al., 2005), 
and in exocrine pancreatic cancer, but not in endocrine pancreatic tumors (Kimura et al., 
1992). Reg Iα is suggested to be a trophic or anti-apoptotic factor in colonic and gastric 
cancer, enhancing Akt phosphorylation and Bcl-xL expression in gastric and colonic cancer 
cell lines (Dieckgraefe et al., 2002, Sekikawa et al., 2005a, Sekikawa et al., 2005b). The 
growth-stimulating effect of Reg Iα has been shown to be mediated by a receptor named Reg-
R, which shows homology to multiple exostoses-like gene (Kobayashi et al, 2000). Yamauchi 
et al. (2009) have shown that PPARγ agonists suppress Reg Iα expression and growth of a 
gastric cancer cell line.  
In esophageal squamous cell carcinoma, Reg Iα expression predicted a good response 
to chemoradiotherapy (Hayashi et al. 2008a, Hayashi et al. 2008b) but it was a marker for a 
poor outcome in advanced gastric cancer (Yamagishi et al., 2009), in colorectal cancer 
(Astrosini et al., 2008, Macadam et al., 2000), in bladder cancer (Geng et al. 2009), in breast 
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cancer (Sasaki et al. 2008) and in non-small cell lung cancer (Minamiya et al. 2008), and 
possibly in hepatocellular carcinoma (Yuan et al., 2005).  
Reg Iα is thus expressed widely in the human body, and it is upregulated during 
inflammation and regeneration, and in cancer. Its role in diabetes is not clear: it clearly 
contributes to the regeneration of pancreatic islet cells, and possibly has a role in the 
development of Type II diabetes, but it seems to be too oncogenic to be of pharmacological 
use in the diseases. To be a useful cancer drug target, on the other hand, Reg Iα is probably 
too ubiquitously expressed and has too many important physiological functions. 
 
 
2.4.2 Reg Iβ  
 
The Reg Iβ gene was first discovered independently by Bartoli et al. in 1993 and by 
Moriizumi et al. in 1994. It is highly similar to Reg Iα, differing only in 22 amino acids. Reg 
Iβ is physiologically expressed in pancreas, apparently in both endocrine and exocrine 
pancreas, and even more abundantly than Reg Iα (Bartoli et al., 1993, Moriizumi et al., 1994, 
Sanchez et al., 2001), and also in liver (Bartoli et al., 1994). Both Reg Iα and Reg Iβ have 
been shown to induce interleukin (IL) -6 production in esophageal squamous cancer cells 
(Usami et al., 2010). Reg I proteins may thus exert their action via IL-6, and a positive 
feedback loop possibly exists between these proteins. Reg Iβ is also upregulated in IBDs, and 
often more strongly than Reg Iα, (Dieckgraefe et al., 2002, Granlund et al., 2011, Lawrance 
et al., 2001), as well as in colonic cancer (Rechreche et al., 1999, Violette et al., 2003). Zheng 
et al. (2011) reported that Reg Iβ expression was more frequent in the mucosa adjacent to 
colonic cancer than in the cancer itself, and that it was an indication of a good prognosis. In a 
cell line established from an esophageal squamous cell carcinoma, Reg1β transfection 
enhanced sensitivity to anticancer treatments (Hayashi et al., 2008a).  
 Thus, Reg Iβ seems to be a cell proliferation-linked protein, as is Reg1α, but in 
contrast to Reg Iα, Reg Iβ appears to be associated with a more favorable prognosis. The 
mechanisms of action are more poorly understood than those of Reg Iα and its potential as a 
drug target is still unclear. 
 
 
2.4.3 The Reg III protein family 
 
Two members of the type III Reg protein family, HIP/PAP and Reg IIIγ, are expressed in 
humans. Due to the large number of type III Reg family members expressed in other species, 
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the reference to human protein in the literature is sometimes confusing (personal observation; 
Parikh et al., 2012). In the following section, the Gene Data Bank nomenclature is used to 
refer to the human orthologue when discussing proteins from other species: mouse/rat Reg 
IIIγ (PAP III) is the orthologue of human HIP/PAP, and the mouse/rat Reg IIIβ (PAP I) is the 
orthologue of human Reg IIIγ, even if the authors had used another referral protein. 
 
 
2.4.3.1 HIP/PAP 
 
HIP/PAP is one of the group III Reg family members. The ‘PAP’ protein was first described 
by Keim et al. (1984) as a protein that is upregulated during pancreatitis in rats. The rat 
cDNA sequence was published by the same group (Iovanna et al., 1991) (although the 
sequence was later renamed Reg3β, and thus now corresponds to human Reg IIIγ). The 
human gene, designated ‘HIP’, was described by Lasserre et al. (1992), who had found it by 
differential screening of a human hepatocellular carcinoma cDNA library. At the time, as 
only one Reg III human gene was known, the previously found rat protein was considered a 
homologue of the new human gene. The first described ‘PAP’-protein is, however, no longer 
considered a human HIP/PAP counterpart, and this causes confusion regarding the 
nomenclature. 
Human HIP/PAP is physiologically expressed in the Paneth cells of the small 
intestine and colon and in enteroendocrine cells that stain with anti-glucagon-antibodies, and 
in glucagon-expressing pancreatic islet cells (Christa et al. 1996, Hervieu et al., 2006). 
Lasserre et al. (1999) reported HIP/PAP expression in the developing nervous system of 
mouse embryo, but they studied the mouse Reg IIIβ gene, which is today considered to 
correspond to the human Reg IIIγ. Accordingly, Matsumoto and colleagues (2011) reported 
that the mouse homologue of HIP/PAP is not expressed in the nervous system of developing 
mouse embryo.  
Similar to other Reg proteins, HIP/PAP is involved in inflammation and regeneration. 
It can form fibrillar, insoluble and protease resistant structures after trypsin cleavage, like Reg 
1α (Graf et al., 2001). The mouse homologue is also involved in motor nerve regeneration 
(Namikawa et al., 2005). It is expressed in the urothelium in interstitial cystitis (Makino 
2010). It has been proposed to display an adhesion function in hepatocytes (Christa et al., 
1996). HIP/PAP serum levels are elevated in liver cirrhosis as well as in hepatocellular cancer 
(Christa et al., 1999). Recombinant human HIP/PAP protein accelerates liver regeneration in 
mice and functions as a hepatocyte proliferative / anti-apoptotic factor (Lieu et al. 2005, 
Moniaux et al, 2011). In HIP/PAP deficiency, studied with a Reg IIIβ-/- knockout mouse 
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model, the mice developed a more severe experimental acute liver failure than did wild type 
mice (Lieu et al., 2006). HIP/PAP expression has been shown to be induced by gut microflora 
(Cash et al., 2006, Ogawa et al., 2003), and Cash and co-workers showed that it functions as a 
part of innate immunity, as it was bactericidal to gram-positive bacteria. It was later shown to 
bind peptidoglycans with its EPN motif (Lehotzky et al., 2010, Mukherjee et al., 2009). 
Increased HIP/PAP expression during inflammatory bowel diseases might be linked to this 
property of bacterial defense (Ogawa et al., 2003).  
Expression of HIP/PAP is induced in several cancer types, including hepatocellular, 
gastric, and pancreatic acinar cancer, glucagon-expressing endocrine tumors, and colonic 
cancer (Cavard et al., 2006, Hervieu et al., 2006, Itoh et al., 1995, Lasserre et al., 1992, 
Rechreche et al., 1999, Zheng et al., 2011). HIP/PAP expression in gastric cancer has, 
however, also been reported to be down-regulated (Choi 2007). Rosty and co-workers (2002) 
described HIP/PAP as a biomarker for pancreatic ductal adenocarcinoma. Interestingly, they 
showed that the protein was rarely expressed in the cancer cells, but more commonly in the 
normal-appearing ductal cells. Fukushima et al. (2005) also reported upregulated HIP/PAP 
expression in peritumoral tissue adjacent to pancreatic cancer. HIP/PAP correlated positively 
with a favorable prognosis in hepatocellular carcinoma (Yuan et al., 2005) and in colonic 
cancer (Zheng et al., 2011). It is proposed to be downstream of Wnt/beta-catenin signaling in 
liver tumors (Cavard et al., 2006). Demaugre et al. (2004) showed that HIP/PAP binds the RII 
alpha regulatory subunit of cAMP-dependent protein kinase in hepatocellular carcinoma cells, 
and alters its signaling. The mitogenic and anti-apoptotic properties of HIP/PAP in the liver 
seem to be mediated at least partly through the protein kinase A (PKA) signaling pathway 
(Simon et al., 2003).  
Thus, HIP/PAP exhibits also multiple functions in regeneration, inflammation, and 
immune defense. Although involvement in proliferation signal cascades is proposed, the most 
important role of HIP/PAP seems to be the orchestrating of the interplay between 
inflammation and cell proliferation. 
 
 
2.4.3.2 Reg IIIγ  
 
The gene sequence of human Reg IIIγ was first described by Nata et al. in 2004. The protein 
shows 85% homology to HIP/PAP (Nata et al., 2004). According to Nata and colleagues 
(2004), it is expressed in pancreas and testis, but not in the intestine. Matsumoto and 
colleagues (2011), however, found the mouse homologue to be expressed in absorptive 
enterocytes.  
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A large part of the information on Reg IIIγ is derived from animal studies that discuss 
the rat and mouse homologs called Reg IIIβ. Two rat Reg III family genes are involved in 
motor nerve regeneration, one of which corresponds to human Reg IIIγ (Namikawa et al., 
2005). Matsumoto et al. (2011) also described a transient upregulation of the mouse gene in 
sensory and motor nerves during embryogenesis and nerve regeneration. It was found to 
participate in the myelination of motor axons (Tebar et al., 2008), and the mouse homolog has 
been shown to act as a motoneuron neurotrophic factor (Nishimune et al., 2000). Also Reg 
IIIγ can form fibrillar, insoluble structures upon trypsin digestion (Graf et al., 2001).  
Rat Reg IIIβ, designated ‘PAP’ in the articles, is upregulated in acute pancreatitis 
(Keim et al., 1984, Iovanna et al., 1991). Malka et al. (2000) proposed an anti-apoptotic 
mechanism to rat Reg IIIβ in pancreatic cells, mediated by MAP kinases. Gironella and 
colleagues (2007) confirmed that mouse Reg IIIβ was an anti-apoptotic and anti-
inflammatory protein in an experimental pancreatitis model. Folch-Puy et al. (2006) studied 
rat Reg IIIβ in a rat pancreatic acinar cell line and found that it inhibits inflammatory 
responses by suppressing NF kappa B activity through a JAK/STAT-mediated mechanism. 
Reg IIIγ was also induced in the gut during bacterial reconstitution experiments in mice 
(Ogawa et al., 2003).  
 Baeza et al. (2001) described a change in mouse Reg IIIβ expression in non-obese 
diabetic (NOD) mice that developed diabetes: after onset of diabetes, the expression shifted 
from islet cells to the surrounding acinar cells.  
Surprisingly, Reg IIIγ has not been reported in cancer. This difference from other Reg 
family proteins might be due to the confusing nomenclature of the type III Reg proteins (see 
above). It is, however, involved in cell proliferation and regeneration. The expression profile 
of Reg IIIγ seems more restricted than that of other Reg proteins, suggesting possibly more 
restricted physiological functions. 
 
 
2.4.3.3 INGAP 
 
A third member of the group III Reg family, Islet Neogenesis Associated Protein INGAP, was 
originally cloned from regenerating guinea pig exocrine pancreas (Rafaeloff et al., 1997). It is 
discussed briefly even though the authors have not been able to identify a human counterpart 
of this gene. The gene product was shown to initiate duct cell proliferation (Rafaeloff et al., 
1997). In developing mouse pancreas, INGAP was expressed in insulin- and somatostatin-
producing islet cells but not in glucagon-producing cells, whereas the opposite was true in the 
adult pancreas (Hamblet et al., 2008). The authors discussed the possibility that this gene 
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might be a marker for endocrine commitment. An antibody raised against the hamster INGAP 
recognized an antigen also in human pancreatic glucagon expressing islet cells, but the 
identity of this protein remains to be elucidated (Taylor-Fishwick et al. 2008). A 
pentadecapeptide derived from the INGAP gene has been shown to increase islet size and 
insulin production in animal models (Pittenger et al., 2007). A proof of concept study has also 
been performed on the treatment of human diabetes mellitus patients with INGAP 
pentadecapeptide administered subcutaneously (Dungan et al., 2009). Patel et al. (2009) 
reported an increase of ‘PAP/INGAP’ protein in mice with somatostatin receptor type 5 
deficiency (SSTR5-/-), but the authors do not specify which Reg gene was in question. 
 
 
2.4.4 Reg IV 
 
Reg IV is discussed in detail in the Results and discussion chapter. The gene was first 
reported independently by Hartupee et al. (2001) and our research group (I). It is a 
phylogenetically more distant Reg protein family member, expressed mainly in the GI tract 
and associated with neuroendocrine and mucinous differentiation (I, II, III, IV). Reg IV is 
overexpressed in IBDs and proliferating goblet cells (I, Granlund et al., 2011). It is present in 
precancerous lesions of the gut mucosa (XH Li et al., 2010, Glebov et al., 2006), in colorectal 
adenomas (Zhang et al., 2003) and cancer (Violette et al., 2003), and also in gastric (Oue et 
al., 2004, Mitani et al., 2007), pancreatic (Takehara et al., 2006), and prostate cancer (Ohara 
et al., 2008), as well as various neuroendocrine cancers (IV, Oue et al., 2005). Reg IV has 
been shown to activate the EGFR/Akt/AP-1 signaling pathway (Bishnupuri et al., 2006), and 
recently it has been shown to modulate other receptor tyrosine kinases (Vanderlaag et al., 
2012). 
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3. Aims of the study 
 
The aim of this study was to find and characterize a gene specifically expressed in 
inflammatory diseases of the gut and in colorectal tumors. A novel gene, Reg IV, was 
identified in gene expression libraries of the human gastrointestinal tract and chosen for 
further characterization. 
 The further aims of the study were  
- to define the chromosomal location and the structure of the Reg IV gene (I) 
- to characterize the protein product encoded by Reg IV gene (I) 
- to study the expression pattern of Reg IV in the normal human body and in gut 
mucosal proliferation (I) 
- to specify the nature of gut neuroendocrine cells that express Reg IV (II) 
- to study the expression of Reg IV in the neoplasia of goblet cells, i.e., mucinous 
appendiceal cystadenoma and pseudomyxoma peritonei, and to compare the 
expression with markers of normal and malignant differentiation (III), and 
- to study Reg IV expression in different types of neuroendocrine tumors and to 
compare its expression with the transcription factor Hath1 (IV). 
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4. Materials and methods 
 
 
The tissue samples for the immunohistochemistry experiments used in all the studies were 
collected from the archives of the Department of Pathology and HUSLAB, Haartman 
Institute, by the collective permission of the Ethics Committee of the Institute. The tissue 
samples were handled anonymously. The patients were caucasian, 3-87-years-old males and 
females who had undergone a surgery or a biopsy had been taken in connection with the 
treatment of their disease. 
The principal other materials and products used in the study are summarized below. 
The materials used in Study I are presented in Table 1, the materials of Study II in Table 2, of 
Study III in Table 3, and of Study IV in Table 4. 
 
Table 1. Summary of materials (reagents, chemicals, antibodies, kits, etc.) used in Study I. 
 
Material used Provider, manufacturer 
Life Seq Database Incyte Pharmaceuticals 
pCR2.1 TOPO, pCDNA3, and pcDNA 
3.1/V5- HisTOPO vectors 
Invitrogen, Carlsbad, CA, USA 
Reg IV polyclonal antibody produced as described in Study I 
ANTI-FLAG M2 monoclonal antibody Sigma, St Louis, MO, USA 
Chromogranin A antibody Zymed, CA, USA 
HRP, FITC and TRITC-conjugated secondary 
immunoglobulins (IgG) 
Dako, Glostrup, Denmark 
TA Cloning Kit Invitrogen, San Diego, CA, USA 
RNA Labeling Kit Boehringer-Mannheim, Mannheim, Germany 
Elite ABC Kit Vectastain; Vector Laboratories, Burlingame, 
CA, USA 
A human genomic plasmid artificial 
chromosome (PAC) clone 
GenomeSystems, Inc., St.Louis, MO, USA 
Human Multiple-Tissue Expression (MTE) 
Array, Multiple Tissue Northern (MTN) blots 
Human II and Human III 
Clontech Laboratories, Inc., Palo Alto, CA, 
USA 
Rabbit reticulocyte lysate, with or without 
canine pancreatic microsomal membranes 
Promega, Madison, WI, USA 
Transfectam reagent Promega, Madison, WI, USA 
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Table 2. Summary of materials (reagents, chemicals, antibodies, and kits) used in Study II. 
 
Material used Provider, manufacturer 
Elite ABC Kit Vectastain; Vector Laboratories, Burlingame, 
CA, USA 
Background Blocker Diagnostic BioSystems, Pleasanton, CA, 
USA 
Reg IV mouse monoclonal antibody raised by us (Study III) 
Reg IV rabbit polyclonal antibody raised by us (Study I) 
Serotonin antibody Dako, Glostrup, Denmark 
Somatostatin antibody Dako, Glostrup, Denmark 
Substance P antibody Abcam, Cambridge, UK 
Peptide YY antibody BioTrend, Cologne, Germany 
Motilin antibody Thermo Scientific, USA 
Secretin antibody Abcam, Cambridge, UK 
Neurotensin antibody Thermo Scientific, USA 
Glucagon Like Peptide-1 antibody BioTrend, Cologne, Germany 
Glucagon Like Peptide-2 antibody BioTrend, Cologne, Germany 
Gastric Inhibitory Peptide antibody Sigma, MO, USA 
Ghrelin antibody Novus Biologicals, CO, USA 
Cholecystokinin antibody Thermo Scientific, USA 
Chromogranin A antibody Zymed, CA, USA 
HRP-conjugated secondary immunoglobulins 
(IgG) 
Dako, Glostrup, Denmark 
 
 
Table 3. Summary of materials (reagents, chemicals, antibodies, and kits) used in Study III. 
 
Material used Provider, manufacturer 
Elite ABC Kit Vectastain; Vector Laboratories, Burlingame, 
CA, USA 
TA Cloning Kit Invitrogen, San Diego, CA, USA 
RNA Labeling Kit Boehringer-Mannheim, Mannheim, Germany 
Hybridization buffer  Sigma, St. Louis, MI, USA 
Digoxigenin nucleic acid detection kit  Roche, Germany 
MUC2, MUC5AC, and MUC6 antibodies Novocastra Laboratories Ltd, New- castle 
upon Tyne, UK 
CDX2 antibody BioGenex, San Ramon, CA, USA 
HRP-conjugated secondary immunoglobulins 
(IgG) 
Dako, Glostrup, Denmark 
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Table 4. Summary of materials (reagents, chemicals, antibodies, and kits) used in Study IV. 
 
Material used Provider, manufacturer 
Elite ABC Kit Vectastain; Vector Laboratories, Burlingame, 
CA, USA 
Background Blocker Diagnostic BioSystems, Pleasanton, CA, 
USA 
Reg IV mouse monoclonal antibody raised by us (Study III) 
Reg IV rabbit polyclonal antibody raised by us (Study I) 
Reg IV mouse monoclonal antibody R&D Systems, Minnesota, MN, USA 
Reg IV rabbit polyclonal antibody R&D Systems, Minnesota, MN, USA 
Hath1 antibody MBL International Corporation (Woburn, 
MA, USA 
CD138 antibody Dako, Glostrup, Denmark 
c-met antibody Dako, Glostrup, Denmark 
MIB-1 antibody Dako, Glostrup, Denmark 
HFG antibody Biocare Medical, Concord, CA, USA 
bFGF antibody Santa Cruz Biotechnology, Heidelberg, 
Germany 
TA Cloning Kit Invitrogen, San Diego, CA, USA 
RNA Labeling Kit Boehringer-Mannheim, Mannheim, Germany 
DIG nucleic acid detection kit  Roche, Germany 
 
 
The materials and methods used are described in detail in the original publications. Table 5 
summarizes these methods and refers to the publication(s) in which they were utilized. A 
brief description of the methods is given below, after Table 5. 
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Table 5. Summary of the methods used. 
 
Method Original publication 
In silico data mining I 
cDNA cloning and sequencing  I 
PCR and gene sequencing I 
Fluorescence in situ hybridization (FISH) I 
Northern blot and dot blot I 
In vitro translation I 
Polyclonal antibody production I 
Monoclonal antibody production III 
Immunohistochemistry I, II, III, IV 
Immunofluorescence and 
doubleimmunofluorescence 
I, II, IV 
Confocal microscopy I, II 
In situ hybridization I, III 
Recombinant DNA techniques I 
Cell culture and transfection I 
Western blot I 
 
4.1 In silico data mining; Reg IV cDNA cloning and sequencing (I) 
 
Small intestine- and colon-derived libraries of the Life Seq database (Incyte 
Pharmaceuticals) were studied and Reg IV mRNA was detected as a cluster of expressed 
sequence tags (EST). A full-length cDNA insert was verified by sequencing.  
Three highly homologous mouse sequences were found using human Reg IV 
cDNA in a BLAST search in the NCBI EST database. The cDNA for the mouse 
orthologue of Reg IV was subcloned. 
 
4.2 PCR and gene sequencing (I) 
 
A human genomic plasmid artificial chromosome (PAC) clone containing the genomic 
sequence of Reg IV was obtained from GenomeSystems, Inc. (St.Louis, MO, USA). The 
insert was amplified by PCR with Reg IV-specific primers, subcloned, and sequenced. 
The sequencing data complemented and verified the genomic sequence data of public 
databases. 
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4.3 Fluorescence in situ hybridization (FISH) (I) 
 
The human genomic PAC clone containing the Reg IV gene was labeled with biotin-16-
dUTP and used as a probe to localize the gene in the human chromosomes. Human 
interphase and metaphase nuclei containing slides were hybridized with the probe, and the 
signal was detected with avidin-conjugated FITC amplified with biotinylated anti-avidin 
antibodies. The slides were counterstained with 4,6-diamino-2-phenyl-indole (DAPI). 
 
4.4 Northern blot and dot blot (I) 
 
Human Multiple-Tissue Expression (MTE) Array and Multiple Tissue Northern (MTN) blots 
Human II and Human III (Clontech Laboratories, Inc., Palo Alto, CA, USA) were used for 
dot blot and Northern blot analyses. A 32P-labeled, full-length Reg IV cDNA was used as a 
probe. To visualize the results, the filters were exposed to Kodak Biomax MS film for 1-3 
days. 
 
4.5 In vitro translation (I) 
 
A full-length Reg IV cDNA was subcloned into the pCDNA3 expression vector in which the 
expression is regulated by the T7 RNA polymerase promoter. To induce the expression, 
rabbit reticulocyte lysate was used, with or without canine pancreatic microsomal 
membranes. 35S-methionine was used to label the products. The proteins obtained were 
analyzed by sodium dodecyl sulfate polyacrylamide (12%) gel electrophoresis (SDS-PAGE), 
and visualized by autoradiography. 
 
4.6 Antibodies (I, III) 
 
A rabbit polyclonal and a mouse monoclonal antibody for Reg IV were created (see 
below). Other, commercially available antibodies are listed in the tables describing the 
matherials used in the studies. 
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4.6.1 Polyclonal antibody production (I) 
 
A C-terminal Reg IV-derived peptide was synthesized and coupled to keyhole limpet 
hemocyanin. It was used to produce polyclonal antibodies in rabbits. The sera were tested 
for reactivity against the peptide with enzyme-linked immunosorbent assay (ELISA), and 
the positive batches were affinity-purified.  
 
4.6.2 Monoclonal antibody production (III) 
 
Mice were immunized with recombinant Reg IV protein mixed with adjuvant. Their 
splenocytes were harvested and fused with FO murine myeloma cells. Solid phase 
enzyme immunoassays (EIA) were performed to assess hybridoma supernatant activity. 
Clones specifically reactive to Reg IV were expanded and subcloned. Monoclonal 
supernatants were purified using protein A. 
 
4.7 Immunohistochemistry (I, II, III, IV) 
 
Sections of 4-5 µm were cut from formalin-fixed, paraffin-embedded tissues. After 
deparaffinization, the sections were heated twice for 5 minutes in citrate buffer in a 
microwave oven (650W). The sections were treated with H2O2 and blocking buffer before 
adding the first antibody. EliteKit (Vectastain; Vector Laboratories, Burlingame, CA, 
USA) was used according to the manufacturer’s instructions for immunoperoxidase 
staining, visualized with 3-amino-9-ethylcarbazole. 
 The immunohistochemistry results were interpreted by Professor Leif Andersson 
for Studies I and III, and by Kukka Heiskala and Leif Andersson for the Studies II and IV. 
 
4.8 Immunofluorescence and doubleimmunofluorescence; confocal microscopy (I, II, 
IV) 
 
Sections of 4 µm were cut from formalin-fixed, paraffin-embedded tissues and 
deparaffinized. They were heated twice for 5-7 min in citrate buffer in a microwave oven 
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(650W) and treated with blocking buffer before treatment with the primary antibody(ies). 
After incubation overnight at +4°C, secondary FITC- and TRITC-conjugated antibodies 
(1:30) were added.  
A conventional fluorescence microscope or confocal microscopy (Leica TCS 
SP2) was used for analyzing the results.  
 
 
4.9 In situ hybridization (I, III) 
 
In situ hybridization probes were prepared by using the TA cloning kit (Invitrogen, San 
Diego, CA, USA). The appropriate cDNA construct was cloned into the TA vector that was 
subsequently linearized. The RNA Labeling Kit of Boehringer–Mannheim (Mannheim, 
Germany) was used to generate digoxigenin-labeled RNA probes by in vitro transcription. 
Tissue sections were deparaffinized and specially prepared for in situ hybridization. 
They were treated with triton X-100 and proteinase K, and postfixed with paraformaldehyde. 
After acetylation, the sections were incubated with a prehybridization buffer, and overlaid 
with hybridization buffer containing 10 ng of digoxigenin-labeled RNA probe. They were 
then covered with plastic coverslips and incubated overnight in a humid chamber at 42°C. 
After hybridization, the sections were washed in SSC. Unbound RNA probe was 
digested with ribonuclease A. The labeled probe was detected using the digoxigenin nucleic 
acid detection kit (Roche, Germany).   
 
4.10 Recombinant DNA techniques, cell culture and transfection, and Western blot (I) 
 
A cDNA encoding Reg IV with a C-terminal FLAG epitope was cloned into a pcDNA3.1/V5-
HisTOPO vector (Invitrogen). The construct was transfected into COS7 cells using 
Transfectam reagent (Promega, Madison, WI, USA) according to the manufacturer’s 
instructions.  
The cells were lysed in Pawson’s buffer. The proteins were separated by 12% SDS-
PAGE and analyzed by Western blotting using the polyclonal anti-Reg IV antibodies and 
monoclonal anti-FLAG antibodies. Horseradish peroxidase (HRP)-conjugated secondary 
antibodies were used and the results were examined by enhanced chemiluminescence. 
MKN45 cells were transiently transfected using Transfectam reagent to express the 
Reg IV construct with a C-terminal FLAG epitope fusion protein. The cells were fixed with 
paraformaldehyde, and permeabilized with 0.05% NP-40. The proteins were visualized with 
immunofluorescence, as described previously.  
 34 
5. Results and discussion 
 
 
5.1 Reg IV gene (I) 
 
The Reg IV gene was found to be located in chromosome 1p12-13.1, whereas the other Reg 
protein genes are clustered in chromosome 2p12. The structure of the gene was partly similar 
to that of the other Reg proteins, i.e., the exon-intron divisions were found in the predicted 
locations, but the intron sequences differed greatly from those of the other Reg genes. The 
Reg IV gene contains large introns of approximately 3 kD. The gene has one main transcript 
and two additional splice variants, but their expressional or functional differences have not 
been studied thus far. 
 
 
Figure 3. Schematic presentation of the Reg IV gene main transcript variant structure. The 
top row shows the length of the whole gene. The second row depicts the sizes of the exons, 
translated areas in black. The third row presents the localization of the exons in the Reg IV 
gene.  
 
Hartupee et al. (2001) published the main transcript of Reg IV. They came to the 
same conclusion as we did: i.e., that Reg IV gene represents a new group of the Reg gene 
family. 
A mouse orthologue was identified in a rodent database and cloned (I). The mouse 
Reg IV cDNA is 70% identical to the human Reg IV cDNA and the preprotein is 66% 
identical and 72% similar to the human Reg IV preprotein. 
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5.2 The Reg IV protein (I) 
 
Reg IV gene was found to encode a preprotein of 158 amino acids with a calculated weight of 
18.229 kD and an isoelectric point of 9.128. It contains a highly hydrophobic signal peptide 
of 22 amino acids, which is digested during processing of the preprotein. The amino acids 37 
through 155 contain a conserved calcium-dependent carbohydrate recognition domain (CRD), 
making it a “C-type lectin”. This conserved domain contains six cysteine residues that form 
intramolecular disulphide bonds (Fig. 2). The predicted secondary structure of Reg IV is thus 
similar to that of Reg Iα, which is a secreted, globular protein. A 3-dimensional model of the 
predicted structure of the protein was created (unpublished results). By its primary structure, 
Reg IV is 37% identical and 47% similar to Reg Iα, 34% identical and 43% similar to 
HIP/PAP, 36% identical and 44% similar to chicken ovocleidin, and 36% identical and 43% 
similar to snake venom galactose-specific lectin. The conserved parts of the protein are 
located on the predicted carbohydrate binding region of the Reg protein family (Hartupee et 
al., 2001). The major differences in the amino acid sequence of Reg IV, compared to the other 
human Reg proteins, are the lack of a five-residue insertion Pro 115-Gly 119 and a six-residue 
insertion close to the amino terminus after Ile 24. Ho et al. (2010) have shown that Reg IV 
displays typical C-type lectin folding, and binds carbohydrates, namely mannan and heparin, 
in a calcium-independent manner. 
The recombinant Reg IV protein was readily detected in Western blot studies (I). 
Proven by in vitro experiments, the predicted signal sequence was cleaved, and a protein of 
approximately 17 kD was formed (I). However, in our Western blot studies of cell line 
protein lysates of both Reg IV transfected and Reg IV naturally expressing cells, we found 
that the predicted-sized protein was difficult to detect (K. Heiskala, unpublished observation). 
Indeed, the protein does seem to form dimers that survive heat treatment at 95°C in the 
presence of SDS and DTT, as shown by Dieckgraefe and coworkers (Li et al., 2003). Reg IV 
requires also specific solubilization conditions when produced in Escherichia coli (Hu et al., 
2010). Hu et al. (2010) described a protocol of producing bioactive Reg IV in E. coli, in 
which refolding after guanidine hydrochloride solubilization required a special protocol of 
optimized refolding buffer. Under these special conditions, Reg IV did not form dimers, and 
was biologically active in stimulating the growth of HCT116 and HT29 cells. 
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5.3 The expression of Reg IV in normal human body (I, II) 
 
5.3.1 Reg IV mRNA expression (I) 
 
Reg IV mRNA was found to be overexpressed in the IBDs by in silico cloning. In dot blot 
and Northern blot studies, the physiological expression of the mRNA in human was largely 
limited to the gastrointestinal tract, mostly to small intestine and descending colon, and to a 
lesser extent to the stomach and the pancreas. Interestingly, the prostate and the testes also 
showed weak expression. Spleen, thymus, leukocytes, lymph nodes, bone marrow, ovary, 
thyroid, adrenal gland, spinal cord, brain, heart, trachea and skeletal muscle displayed no Reg 
IV mRNA expression. Table 6 summarizes the results. 
 
 
Table 6. Reg IV mRNA expression in adult human organs according to staining intensity of 
Reg IV probe in Northern blot and dot blot experiments. +++, very strong expression, ++, 
strong expression, +, weak or very weak expression, -, no detectable expression. 
 
Organ Reg IV mRNA expression 
Stomach + 
Duodenum +++ 
Jejunum ++ 
Ileum +++ 
Ileocaecum ++ 
Appendix + 
Ascending colon + 
Transverse colon + 
Descending colon ++ 
Rectum + 
Pancreas ++ 
Prostate + 
Testis + 
Ovary - 
Thyroid - 
Adrenal gland - 
Thymus - 
Spleen - 
Lymph node - 
Bone marrow - 
 
 
The fetal human tissues included in a commercially available dot blot were negative. 
However, Schröder et al. (2006) have shown that Reg IV mRNA is specifically upregulated in 
the mouse intestine during embryonic days 15-16, and the expression pattern is also spatially 
restricted. Reg IV RNA was detected in the small intestine and in the distal colon, indicating a 
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role in intestinal development. Interestingly, while the expression pattern in the small 
intestine resembled that of an adult, all the epithelial cells of the crypt bottoms in the distal 
colon stained diffusely in in situ hybridization. (Schröder et al., 2006.) Thus, the staining 
pattern in embryonic mouse colon resembled that seen in IBDs or in malignancies (see 
below). 
 
 
5.3.2 Reg IV protein expression (I, II) 
 
5.3.2.1 Reg IV in the gut (I, II) 
 
Reg IV protein expression was detected in the gut, as expected. Two different expression 
patterns were distinguished: strongly staining individual enterocytes of the small intestine and 
colon, and more diffusively and faintly staining goblet cells that were found especially in the 
colon (I). These staining patterns are shown in Figure 4. 
 
 
Figure 4. Reg IV immunohistochemical staining of the small intestine. The left panel shows 
the typical staining pattern of the duodenum, where Reg IV positive, strongly staining 
individual cells are seen along the crypt ad villus (arrowheads). The right panel shows Reg IV 
staining pattern of ileum. Here, in addition to the individual strongly staining cells, goblet cells 
show more diffuse Reg IV positivity. Original magnifications x20. 
 
In normal small intestine, Reg IV protein was mainly expressed in a subpopulation of 
the epithelial cells, primarily of neuroendocrine origin (enteroendocrine cells, EEC). The 
 38 
majority of the Reg IV positive cells expressed the neuroendocrine marker chromogranin A 
(CgA), but both Reg IV negative and CgA positive and Reg IV positive and CgA negative 
cells were also observed (I, II, Fig. 5.). Li et al. (2003) also reported two different types of 
ileal Reg IV staining cells: argentaffin staining neuroendocrine cells of the villus, and a cell 
population located deeper in the crypt that was indistinguishable from other enterocytes.  
 
 
Figure 5. Double immunofluorescence staining of Reg IV (left panel) and chromogranin A 
(middle panel) in jejunum. The merge picture (right) shows that the two proteins are 
expressed in partly different granules. Original magnification x400. Adapted from Study II. 
 
Most Reg IV positive cells contained serotonin (5HT) along the gut, but both Reg IV 
positive and 5HT negative, and 5HT positive and Reg IV negative cells existed in small 
numbers (II). Substance P was co-expressed with Reg IV in the ileum (II). Interestingly, 
although somatostatin and Reg IV were expressed in different cell populations in the small 
intestine, they were co-expressed in the colon and appendix (II). Also ghrelin was co-
expressed with Reg IV only in colon (II). These differences might reflect the different roles 
for Reg IV in the two different regions of the GI-tract, and the results add to the growing data 
that small intestinal and colonic EECs differ conciderably from each other.  
A highly variable co-expression (0-70%) with Reg IV was detected with several other 
gut hormones (GLP (glucagon like peptide) -1, GLP-2, peptide YY, and secretin) (II). GLP-1, 
GLP-2 and PYY are physiologically expressed in an EEC group called the L-cells, but their 
co-expression pattern with Reg IV was rather variable. GLP-1 was very rarely co-expressed 
with Reg IV in the small intestine and colon (0-5%). GLP-2 was found co-expressed with Reg 
IV in some duodenal EECs, forming a conspicuous staining pattern in which GLP-2 localized 
to the central part of the cell and Reg IV to the periphery. Sometimes it was also co-expressed 
with Reg IV in the colon (0-70%). PYY, on the other hand, was relatively often (10-20%) 
seen as a staining of a few granules in a Reg IV expressing cell, mostly in colon, but also 
occasionally in the distal small intestine. Of these markers, GLP-2 has been shown to be 
associated with gut epithelial proliferation and cancer (Back et al., 2003, Gunawardene et al., 
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2011). It is thus conceivable that it was most often co-expressed with Reg IV. Secretin was 
rarely (0-10%) expressed in Reg IV staining cells. The results are summarized in Table 7. 
 
 
Table 7. Summary of the hormones and markers for which the co-expression with Reg IV 
was studied. +, most neuroendocrine cells co-express the proteins, (+), a part of the 
neuroendocrine cells express both proteins, -, no co-expression. ‘Not expressed’ = the protein 
in question is not physiologically expressed in this part of the GI tract. 
 
Antigen Co-expression with Reg IV in 
the small intestine 
Co-expression with Reg IV in 
colon and appendix 
Chromogranin A + + 
Serotonin + + 
Somatostatin - + 
Substance P + (not expressed) 
Ghrelin - + 
GLP-1 (+) - 
GLP-2 (+) (+) 
Secretin (+) (+) 
Peptide YY (+) (+) 
GIP - (not expressed) 
Neurotensin - (not expressed) 
Motilin - - 
Cholecystokinin - - 
 
 
Thus, serotonin was nearly universally co-expressed with Reg IV, except in the 
stomach where Reg IV is not expressed in endocrine cells. Nevertheless, the other hormones 
studied showed diverse and apparently changing co-expression profiles, reflecting a flexible 
and dynamic expression system. It is possible that Reg IV is involved in the maturation 
process of these cells, but other methods are needed for studying this. The complicated 
regulation of protein expression in enteroendocrine cells permits them to adjust to the 
conditions prevailing in the gut epithelium. Interestingly, these cells and their secreted 
proteins are involved also in inflammatory processes (Rindi et al., 2004), a role proposed also 
for Reg IV.   
Reg IV co-localized in EECs with markers associated with inflammation and cell 
proliferation, such as substance P (SuP) and ghrelin. SuP has been linked to gut inflammation 
and IBDs (Margolis and Gershon, 2009). Also ghrelin is associated with IBDs (Hosomi et al., 
2008, Konturek et al., 2009, De Smet et al., 2009), with possibly overlapping signaling 
cascades with SuP (De Smet et al., 2009). What is more, Reg IV shares signaling pathways 
with SuP. Substance P has been shown to transactivate the epidermal growth factor receptor 
(EGFR) (Margolis and Gershon, 2009), a function also proposed for Reg IV in colon 
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adenocarcinomas, where Reg IV has been shown to activate the EGFR/Akt/AP-1 signaling 
pathway (Bishnupuri et al., 2006). Thus, the role of Reg IV in EECs may have to do with its 
functional involvement in inflammation and growth. 
Reg IV expression in the intestine is partly controlled by the NF-κB RelA gene, 
which mediates immunological responses (Steinbrecher et al., 2008). Mice lacking this gene 
were susceptible to dextran sulphate sodium-induced colitis, their epithelial proliferation and 
apoptosis rates were high, and their Reg IV expression level was low (Steinbrecher et al., 
2008). This immunological connection may be a link between neuroendocrine type and goblet 
cell type Reg IV expression, as both cell types participate in inflammation process. 
As mentioned previously, Reg IV has another type of intestinal expression as well, 
i.e., the faint cytoplasmic staining of goblet cells (I). This expression pattern was seen mainly 
in colonic goblet cells, and the physiologic expression level was low. Similar very faint Reg 
IV staining is seen in exocrine pancreatic cells (III). Reg IV expression in goblets was 
induced in proliferation, such as intestinal metaplasia of the esophagus and in IBDs (I).  
  
 
5.3.2.2 Reg IV in other parts of the GI-tract (I, III) 
 
Immunohistochemistry with the polyclonal Reg IV antibody showed clear expression in the 
parietal cells of the stomach, whereas gastric endocrine cells were negative (I). Interestingly, 
the monoclonal Reg IV antibody used did not stain the parietal cells (II). 
Reg IV expression in the pancreas has been debated. The RNA dot blot used showed 
positive Reg IV expression in the pancreas and this observation was confirmed with an RT-
PCR experiment (I). It was shown by immunohistochemistry that normal pancreatic islet cells 
do not stain with the Reg IV antibody used, nor with commercially available Reg IV 
antibodies (III). The exocrine pancreas stained weakly (III). FY Li et al. (2010) and Takehara 
et al. (2006) have published identical findings. However, others have demonstrated Reg IV 
expression in the endocrine pancreas (Oue et al., 2005). This discrepancy might be due to 
differences in the tissue specimens. For instance, Reg Iα expression is induced only in 
proliferating islets (Kimura et al., 1992, Okamoto et al., 1999, Rouquiert et al., 1991, Unno et 
al., 1993, Watanabe et al., 1994). This could be the case with Reg IV as well. In fact, Hu et al. 
(2011) have reported that Reg IV expression level is barely detectable in normal endocrine 
pancreas, and it is induced during experimental pancreatitis in mice. On the other hand, some 
Reg IV antibodies may cross-react with other Reg proteins, explaining the contradictory 
results. 
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5.3.2.3 Reg IV in other parts of the body (unpublished results) 
 
Because of the universal expression of Reg protein during neuronal development, Reg IV 
expression in the brain was studied further. No positive Reg IV staining could be detected by 
immunohistochemistry (unpublished results). Normal prostate or testis tissue was not 
immunohistochemically stained in this work, but Gu et al. (2005) reported no expression in 
normal prostate tissues. They stained in a series of prostate cancers on a tissue microarray, 
using in situ hybridization. Ohara et al. (2008) reported Reg IV expression in several luminal 
epithelial cells of the prostate. Immunohistochemistry of Reg IV in the testes has not been 
reported thus far. Weak Reg IV expression in the normal adrenal medulla and parathyroid 
tissue was shown by immunohistochemistry (IV). 
 
 
5.4 Reg IV in inflammation and cell proliferation (I, IV) 
 
 
Figure 6. Immunohistochemical staining with Reg IV antibody of the inflamed epithelium of 
the ileum of a patient with Crohn’s disease (A) and of colon of a patient with colitis ulcerosa 
(B). Original magnification x 200. Adapted from Study I. 
 
Upregulated expression of the Reg IV protein in epithelial cells at regenerating margins of 
gastric ulcers, in goblet cells of intestinal metaplasia in the esophagus and stomach, and in 
inflammatory bowel diseases (IBDs), both in Crohn’s disease (CD) and in ulcerative colitis 
(UC), was detected (I, Fig. 6.). The overexpression of Reg IV in ulcerative colitis was further 
confirmed by Nanakin et al. (2007) and Granlund et al. (2011). Moreover, Reg IV was 
reported to be already overexpressed in aberrant crypt foci in colon, i.e., in the earliest 
detectable precancerous lesions of the epithelium (Glebov et al., 2006). Overexpression was 
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also often seen in the histologically normal appearing epithelium adjacent to a malignant 
lesion (Heiskala K., unpublished observation). Granlund et al. (2011) have also reported 
upregulation of expression in histologically normal appearing epithelium of UC and CD 
patients. Thus, Reg IV expression seems to be an early reaction to changing conditions in the 
epithelium. Bishnupuri et al. (2006) showed that Reg IV is involved in the activation of the 
EGFR/Akt/AP-1 signaling pathway, and that Reg IV induces the expression of anti-apoptotic 
proteins Bcl-2, Bcl-XL, and survivin. In cell line experiments, recombinant human Reg IV 
protein enhanced the growth of HT29 colon cancer cells in a dose-dependent manner 
(Bishnupuri et al., 2006). Furthermore, Nanakin et al. (2007) have shown that TGF-α, EGF, 
bFGF and HGF induced Reg IV expression in the SW403 colon cancer cell line, and that Reg 
IV overexpression could protect the DLD-1 colon cancer cells from H2O2-induced apoptosis.  
This suggests that Reg IV expression might provide a growth advantage and survival 
advantage to the epithelial cells via reduced apoptosis. On the other hand, the results of 
Steinbrecher et al. (2008) suggest that Reg IV might be involved in the immunological 
defense mechanisms of the epithelium, even though the authors interpret Reg IV to be a 
protein that regulates proliferation. 
From an anatomical point of view, Reg IV expression in inflammation and/or cell 
proliferation differs from the normal situation. Although Reg IV is physiologically expressed 
in neuroendocrine cells of the gut, during inflammation and cell proliferation, the expression 
pattern is wider in epithelial cells in general, and particularly in goblet cells. Normal goblet 
cells stained weakly for Reg IV in immunohistochemistry, while proliferating goblets stained 
intensely, like normal neuroendocrine cells (I, Fig. 6).  
Because of the association of Reg IV with inflammation and cell proliferation, we 
studied the effect of several cytokines on MKN-45 gastric cancer cells and on T84 and 
LS174T colorectal cancer cells that express Reg IV. Quantitative RT-PCR was used to 
measure changes in the Reg IV expression level. IL-1β, IL-6, TNF-α, TGF-β, EGF, HGF, or 
gastrin did not have any effect on Reg IV expression (K. Heiskala, unpublished results). 
In order to study the role of Reg IV in the inflammation and/or proliferation signaling 
cascades, we attempted to identify proteins that interact with Reg IV. A yeast two-hybrid 
screen of a gut EST library was performed using Reg IV cDNA, but no relevant hits were 
found (K. Heiskala, unpublished results). We then attempted to identify a receptor or other 
interacting protein for Reg IV from a small intestinal cDNA λ phage protein expression 
library, using a protocol modified from Kobayashi et al. (2000). Briefly, the proteins 
expressed by the phages were bound on cellulose filters, onto which recombinant Reg IV 
protein was added, but Reg IV did not bind to any of these (K. Heiskala, unpublished results). 
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The negative results might have to do with the dimerization process of Reg IV protein and/or 
the specific solubilization conditions required to obtain monomeric protein. 
Additionally, due to the evident association of Reg IV with cell proliferation, we 
screened approximately 50 peptide-like G-protein coupled orphan receptors (GPCR) in a Ca2+ 
assay with receptors co-expressed with G α 16 or G qi5 chimerical G protein. This search did 
not give any positive results, however (K. Heiskala, unpublished results). 
Finally, to assess the role of Reg IV in the intestinal epithelium, a mouse model was 
created, in which the Reg IV mouse homologue was overexpressed under a villin promoter 
that directs the expression into the gut epithelium. Reg IV overexpression was verified using 
quantitative RT-PCR and immunohistochemistry. The mice developed and reproduced 
normally, and no polyps, adenomas or cancer developed on the intestinal epithelium even 
after long-term follow-up. The mice were then challenged with an experimental colitis 
induced with dextran sulphate sodium. There were no obvious differences between the Reg 
IV overexpressing group and the wild type group in the severity of symptoms (K. Heiskala, 
unpublished results). 
 Thus, the current results regarding the function(s) of Reg IV in proliferation remain 
descriptive, but they nevertheless support the data reported by others. Because Reg IV 
seemed to be a proliferation-associated protein, its expression in neoplasms was studied. 
 
 
5.5 Reg IV in neoplasia (III, IV) 
 
Because Reg IV is associated with cell proliferation and with mucinous or neuroendocrine 
differentiation, and because it has been found in colorectal adenoma and cancer (Nanakin et 
al., 2007, Violette et al., 2003, Zhang et al., 2003), we investigated Reg IV expression in 
mucinous lesions appendiceal mucinous cystadenoma and pseudomyxoma peritonei (III) as 
well as in various neuroendocrine tumors (IV). 
 
 
5.5.1 Reg IV in the appendiceal mucinous cystadenoma and pseudomyxoma peritonei 
(III) 
 
Reg IV overexpression in proliferating goblet cells prompted us to study its expression in 
other diseases involving goblet cell differentiation and mucus production. As expected, Reg 
IV was upregulated in the appendiceal mucinous cystadenoma and in pseudomyxoma 
peritonei. 
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Reg IV was positive in all the samples of this material (Table 8). Normal appendices 
(6) showed clear Reg IV positivity (+). Most adenomas (8/10) showed very strong positive 
staining (3+) or (2/10) strong staining (2+). Our pseudomyxoma peritonei samples 
represented disseminated peritoneal adenomucinosis type according to the classification of 
Ronnett et al. (2001), corresponding to low-grade mucinous adenocarcinoma of the WHO 
classification. They showed either strong (2+, 5/9), or moderate (+, 3/9) or, less often, very 
strong (3+, 1/9) Reg IV positivity. The number of samples is too small for drawing 
statistically significant conclusions. The results nevertheless imply that Reg IV expression 
could, after an initial upregulation, be downregulated during malignant transformation. The 
typical staining results are shown in Figure 7. 
 
 
 
 
 
 
 
 
Figure 7. Immunohistochemical staining of 
Reg IV (a-c), CDX2 (d-f) and MUC2 (g-i) in 
normal appendix (a, d, g), appendiceal 
mucinous cystadenoma (b, e, h), and in 
pseudomyxoma peritonei (c, f, i). Reg IV 
stains strongly the neoplastic epithelium of 
appendiceal mucinous cystadenoma (b) 
and PMP (c), but stains only the 
neuroendocrine cells of the normal 
epithelium (a, arrows). CDX2 is positive in 
normal (d) and neoplastic epithelium (e-f), 
as is MUC2 (g-i). Original magnification 
x100. 
 
 
 
 
 
 
 
 
 
 
 
 
In the same study, we also studied the co-expression of Reg IV with the caudal 
homeodomain transcription factor CDX2 and the mucins MUC2, MUC5AC and MUC6. The 
immunohistochemistry staining results are summarized in Table 8. 
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Table 8. The immunohistochemical staining results of appendiceal mucinous cystadenoma 
(‘adenoma’) and PMP. 10 adenomas and 9 PMPs were stained. The table shows the most 
common staining result and the number of specimens showing this result on the first row, 
followed by the less common staining patterns and numbers on the following rows. +++, very 
strong staining, ++, clear positive staining, +, weak or patchy staining, -, no staining. 
 
 Reg IV CDX2 MUC2 MUC5AC MUC6 
Adenomas 
(10) 
+++ (8/10)  
++ (2/10) 
++ (8/10)  
+++ (1/10)  
+ (1/10) 
++ (6/10)  
+++ (4/10) 
++ (6/10) 
+ (2/10) 
+++ (2/10) 
+ (5/10) 
- (5/10) 
PMPs (9) ++ (5/9) 
+ (3/9) 
+++ (1/9) 
++ (9/9) +++ (6/9) 
++ (3/9) 
++ (6/9) 
+++ (3/9) 
- (9/9) 
 
 
CDX2 is a regulator of intestinal differentiation. It has been proven to be essential for the 
development of all types of intestinal cells during organogenesis (Stringer et al., 2012). CDX2 
regulated the expression of MUC2 in transfected COS-7 cells (Yamamoto et al. 2003). 
Moreover, transgenic mice with ectopic expression of CDX2 targeted at the gastric mucosa 
progressively lost parietal cells, and eventually developed intestinal metaplasia of the entire 
gastric mucosa (Mutoh et al. 2002). Importantly, a CDX2 binding site was also found in the 
predicted promoter region of Reg IV gene (I). Reg IV and CDX2 were partly co-expressed in 
the adenomatous epithelium in this study (III, Fig. 7). Other immunohistochemical studies 
(Sentani et al., 2008; Yamagishi et al., 2009) have also revealed coexpression of Reg IV with 
CDX2. However, as CDX2 is constitutively expressed also on normal epithelium, its 
physiological expression does not seem to be enough to drive Reg IV expression (Fig. 7). In 
their reviews, Yasui et al. (2009; 2011) suggest a direct regulating effect of CDX2 through 
HOXA10 on Reg IV expression in MKN-45 gastric cancer cells, but so far they have not 
published their results in detail. It is plausible that CDX2 expression is needed to trigger Reg 
IV expression in intestinal type of gastric cancer, in which Reg IV expression is ectopic. But, 
since Reg IV is not expressed universally along with CDX2, other factors are apparently 
needed to induce its expression. As for the other molecules that regulate Reg IV expression, 
Wang et al. (2011) recently proposed that a Hedgehog signaling molecule, GLI1, would 
regulate Reg IV expression, at least in pancreatic cancer. 
MUC2, an intestinal type mucin, was partly co-expressed with Reg IV (Fig. 7). 
MUC2 staining was, however, also seen in normal goblet cells that did not stain for Reg IV. 
Its expression was upregulated in adenomas and PMP, and it did not show a similar relative 
downregulation as did Reg IV expression in PMPs. 
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Co-expression of Reg IV with MUC5AC was found in adenomas but not in normal 
appendices (III). However, the cellular distribution of the two proteins in adenomas was 
dissimilar. Reg IV was found all along the epithelium, whereas MUC5AC positivity was seen 
only in the upper, luminal portions of the glands. This may indicate that while Reg IV and 
MUC5AC de novo acquisition mechanisms probably converge upstream, when the 
proliferating goblet cell phenotype is formed, the fine-tuning of their expression is regulated 
by different mechanisms. 
It is intriguing that in five out of six appendiceal mucinous cystadenomas of female 
patients, MUC6 stained positive in the basal portions of the glands that were negative for 
MUC5AC (III). This phenomenon was not seen in male patients. It is known that steroid 
hormones can influence the expression of MUC6 at least in breast cancer cells (de Bolós et 
al., 1998). This might have some bearing on the fact that the incidence of appendiceal 
mucinous cystadenomas and the PMP is slightly higher females. 
XH Li et al. (2010) have studied the co-expression of Reg IV with mucins in 
colorectal cancer, and they found co-expression with MUC2 but not with MUC5AC. Nakata 
et al. (2009) have studied intraductal papillary mucinous neoplasms of the pancreas; they 
found that even though MUC2 and Reg IV expression were often correlated in the intestinal 
type of these tumors, tumors of gastric type tended to express Reg IV without MUC2 
expression.  
Thus, while Reg IV was partially spatially co-expressed with CDX2 and mucins, this 
study did not directly imply common mechanisms of transcription regulation. As an intestinal 
goblet cell marker, Reg IV could help in localizing primary tumors in unclear cases of PMP 
or mucinous carcinoma metastases. This, on the other hand, is not completely straightforward, 
either, as Reg IV expression can be found in several different kinds of mucinous tumors. 15 
out of 73 (20%) of mucinous ovarian tumors expressed Reg IV to some extent (K. Heiskala, 
unpublished results), as well as one of four breast infiltrating ductal cancers (FY Li et al., 
2010), and about 30% of intraductal papillary mucinous neoplasms of the pancreas (Nakata et 
al., 2009, and K. Heiskala, unpublished results). Reg IV overexpression has also been found 
in adenoid cystic carcinoma of the salivary gland (Sasahira et al., 2008) and in prostate cancer 
(Hayashi et al., 2009, Ohara et al., 2008).   
 All in all, even though Reg IV expression is more common in mucinous 
malignancies of the GI-tract, it has also been detected in cancers of other origins. Reg IV 
showed some spatial correlation with intestinal and mucinous markers, but no convincing 
common regulatory mechanism has been demonstrated so far. 
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5.5.2 Reg IV in neuroendocrine tumors (NET) (IV) 
 
To further investigate the role of Reg IV in neuroendocrine differentiation and neoplasms, we 
investigated the expression of Reg IV in a panel of 63 neuroendocrine tumors. Co-expression 
with the basic helix-loop-helix (bHLH) transcription factor Hath1 was assessed to shed light 
on the possible interrelationship with Reg IV and the Notch signaling pathway. 
As expected, Reg IV was strongly expressed in most of the neuroendocrine tumors of 
gastrointestinal origin (IV). It was positive in 3/4 NETs of the stomach, in 10/11 NETs of the 
small intestine, in 7/7 NETs of the appendix, and in 2/3 tumors of the rectum. Co-expression 
with Hath1 was seen particularly in the appendix, but it was not constant. However, the 
expression profiles of both proteins remained similar in the metastases. The results are 
summarized in Table 9. 
 
 
Table 9. Summary of the NET staining results. The proportions of positive staining of Reg IV 
and Hath1 are shown in the two left-hand columns and the co-expression proportions in the 
two right-hand columns. 
 
Localization of the 
NET 
 
Reg IV 
positivity 
Hath1 
positivity 
Hath1 positivity in 
Reg IV + cases 
Reg IV positivity 
in Hath1 + cases 
Stomach 3/4 0/3 0/2 - 
Small intestine 10/11 8/11 8/10 8/8 
Appendix 7/7 7/7 7/7 7/7 
Rectum 2/3 2/3 1/2 1/2 
Pancreas 1/10 9/9 1/1 1/9 
Thymus 0/2 0/2 - - 
Lung 2/12 4/12 0/2 0/4 
Skin (Merkel’s Ca) 2/2 1/2 1/2 1/1 
Parathyroid 4/5 2/2 1/1 1/2 
Thyroid 0/1 1/1 - 0/1 
Adrenal gland 0/6 5/6 - 0/5 
 
 
Interestingly, Reg IV expression was often confined to the outer cell layer of the 
neuroendocrine tumor, leaving the center of the tumor unstained (Fig. 8). The reason for this 
phenomenon is not known. It might reflect the interdependence of the tumor and its stroma, 
where stromal growth factors would induce cell proliferation and/or Reg IV expression, as 
Reg IV is associated with cell proliferation according to several studies. On the other hand, as 
Reg IV is a secreted protein, and as neuroendocrine tumors often cause very little 
inflammatory reaction in the surrounding tissues, Reg IV may have a function in regulating 
the immune defense against the tumor. As a lectin, Reg IV might have an important role in 
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binding other molecules, e.g. leukocytes or bacteria. Granlund et al. (2011) suggested this in 
their article on Reg proteins in IBDs. Ho et al. (2010) have shown that Reg IV binds at least 
mannan and heparin, and they proposed the possibility that Reg IV might bind Helicobacter 
pylori.  
 
 
 
 
 
 
 
 
Figure 8. Immunohistochemical staining of 
an ileal NET with antibodies to Reg IV (a), 
Hath1 (b), bFGF (c), CD138 (d), HGF (e) 
and c-met (f). Reg IV stains positive in the 
outer cell layer of the lesions (a), as does 
Hath1 (b), bFGF (c) and c-met (f). CD138 
is positive on the cell membranes (d) and 
HGF throughout the tumor (e). 
 
 
 
 
 
Reg IV was also expressed in other types of neuroendocrine tumors (Table 9). Reg IV 
was expressed in 1/10 NETs of the pancreas, in 2/12 NETs of the lung (both small cell lung 
carcinomas, SCLC), in 2/2 Merkel carcinoma of the skin, and in 4/5 NETs of the parathyroid. 
Reg IV staining was negative in NETs of the thymus (2), thyroid (1) and adrenal gland (3 
pheochromocytomas and 3 paragangliomas). Thus, Reg IV expression was not restricted to 
the GI-tract tumors.  
The low/negative expression of Reg IV in pancreatic tumors was not surprising, 
considering the fact that Reg IV is not expressed in the endocrine pancreas. Oue et al. (2005), 
however, reported Reg IV expression in 5 (21.7%) of 23 ductal adenocarcinomas of the 
pancreas, and FY Li et al. (2010) in 3/5 pancreatic adenocarcinomas, but Reg IV expression is 
probably caused by different mechanisms in non-neuroendocrine tumors.  
The Reg IV expression profile in the lung was intriguing, as only a subset of the 
SCLCs stained for Reg IV and, as in the positive tumors, areas of intense Reg IV positivity 
and total negativity alternated in a map-like manner. This focal staining pattern has been 
reported in other tumor types as well (Nakata et al., 2009). Oue et al. (2005) did not find Reg 
IV expression in lung cancers, but they did not include SCLCs in their study.  
Reg IV was expressed also in tumors of the mechanoreceptors of the skin, Merkel’s 
carcinoma, and in parathyroid adenomas and carcinomas. This finding further suggests that 
the regulation of Reg IV expression is not a simplistic, mechanical phenomenon associated 
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with the gastrointestinal phenotype, but there are other, unknown factors that play a role in 
the regulation. 
Data has been published on Reg IV expression in neuroendocrine tumors also by 
others. FY Li et al. (2010) reported a study on a panel of 19 endocrine tumors. They found 
Reg IV expression in gastrointestinal tumors and in the tumors of adrenal medulla, but not in 
other extra-intestinal tumors. However, they did not specify which other tissues they had 
studied and found negative. Even though the tumors of the adrenal gland were negative in the 
current material, weak Reg IV expression was found in normal adrenal medulla, which is in 
line with the results of FY Li et al. (2010). Oue et al. (2005) have also reported a strong Reg 
IV expression in the NETs of the colorectum. They studied the co-expression of Reg IV with 
chromogranin A in the NETs, and found that it was not consistent. Moreover, in a third study 
by Sentani et al. (2010) on gastric cancers with neuroendocrine differentiation, Reg IV 
expression was associated with gastrin, serotonin, pancreatic polypeptide and somatostatin. 
They found Reg IV expression in 23% of the gastric cancers, most showing neuroendocrine 
differentiation. They did not include other types of NETs, however. 
In this study of Reg IV on NETs, Hath1, the homologous human counterpart of the 
Drosophila Atonal and the mouse Math1, was included because of its role in intestinal 
differentiation. Math1 is a downstream protein in the Notch signaling pathway and it is 
involved in the differentiation of epithelial, neural, and inner ear hair cells (Ben-Arie et al., 
1997, Bermingham et al., 1999, Machold et al., 2007, Yang et al., 2001). Hath1 is 
physiologically expressed in a subpopulation of small intestinal EECs, whereas in colon the 
expression is concentrated at the bottom of the crypts (Yang et al., 2001). A targeted Math1 
gene deletion in the intestine resulted in differentiation towards absorptive cells and in the 
absence of the secretory lineage epithelial cells, i.e., the intestinal goblet, enteroendocrine, 
and Paneth cells (Schroyer et al., 2007, Yang et al., 2001). Leow et al. (2005) reported a 
down-regulated expression of Hath1 in colorectal cancer, suggesting its tumor suppressive 
function. Park et al. (2006) reported co-expression of Hath1 and the goblet cell marker MUC2 
in intestinal neoplasms. Moreover, the Park’s group found upregulated expression of Hath1 in 
cells of hyperplastic polyps, in adenomas and mucinous cancers, as well as in signet ring 
carcinomas of the intestine, but not in non-mucinous cancers of the gut. These observations 
suggest that Hath1 protein degradation may be required to retain colonic cancer in an 
undifferentiated state. 
Reg IV and Hath1 did not, however, seem to share common regulatory mechanisms. 
Co-expression with Hath1 was seen in some NETs, especially in the intestine, but the proteins 
mostly had divergent expression profiles (Table 9, IV). In normal small intestinal epithelium, 
Hath1 and Reg IV were co-expressed in some EECs, but most of the expression was confined 
to individual cells. Thus, the co-expression was not studied further. 
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The co-expression of Reg IV with CD138, c-met, bFGF and HGF was also studied in 
ileal neuroendocrine tumors (Fig. 8). Nanakin et al. (2007) have previously reported that the 
treatment of human colon cancer cell line SW403 with TGFα, EFG, bFGF or HGF induced 
Reg IV expression, and that the expression levels of bFGF and HGF correlated with the Reg 
IV level in the inflamed epithelium in ulcerative colitis. Bishnupuri et al. (2006) have shown 
that Reg IV can activate the EGFR/Akt/AP-1 signaling pathway in HCT116 and HT29 colon 
cancer cells, and thus a positive feedback loop is possible between these signaling systems. 
This observation of the activation of EGFR signaling was repeated by Ohara et al. (2008) in 
the LNCaP prostate cancer cell line. Rafa et al. (2010) found that Reg IV acts as a mitogenic, 
motility and pro-invasive factor in colon cancer cells, and that the effects were mediated by 
PI3K/Akt, PKAs, PKCs and Rho-like GTPases. In this study, the peripheral cell layers of the 
tumors stained positive for bFGF, as for Reg IV. CD138, the common bFGF receptor, stained 
positive in the cell membranes of all cell layers. HGF expression was also seen throughout the 
tumor, whereas its receptor, c-met, revealed strong reactivity in the peripheral cell layer. The 
findings are in line with previous reports and support the assumption of a cross-talk between 
these regulatory systems. 
Most of the neuroendocrine tumors expressed Reg IV in a perinuclear, strongly 
staining pattern. However, among this series, mucocellular gastric cancers showed an 
intracytoplasmic expression pattern similar to that of the mucinous malignancies and 
proliferating goblet cells (IV). The reason for these different staining patterns is not clear, but 
it is possible that the mucous and endocrine tumor types share also other features in addition 
to Reg IV expression. Bakkelund et al. (2006) demonstrated that 8/11 diffuse signet ring cell 
gastric cancers expressed neuroendocrine markers, suggesting a neuroendocrine origin. 
 
 
5.5.3 Reg IV in cell lines (unpublished results) 
 
Thus, two different expression profiles for Reg IV exist in different tissues and tumor types, 
i.e., perinuclear staining of individual cells, and/or diffuse cytoplasmic staining in virtually all 
epithelial cells. A similar phenomenon is also seen in cell lines. MKN28 and MKN45 gastric 
cancer cell lines express Reg IV as a cytoplasmic staining in virtually all the cells (K. 
Heiskala, unpublished observation). On the other hand, T84 and LS174T colorectal cancer 
cell lines do not express Reg IV in all cells, but exhibit a peculiar pattern of strongly staining 
individual cells and negative cells, despite several passages of the cells (K. Heiskala, 
unpublished observations). Reg IV may have different functions in different organs, and a 
paracrine mechanism of action is possible in the CRC cell lines. These cells might exhibit a 
lateral inbition type of expression regulation, in which Reg IV would regulate its own 
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expression by paracrine negative feedback loops. The exact mechanisms are yet to be 
discovered. 
Moreover, LS174T cells were studied further by single cell cloning to establish a 
variant that would express Reg IV in every cell. Despite several subclonings, such a cell line 
was not achieved, even though a more strongly expressing variant and a nearly negative 
variant were created. No difference was found in the proliferation rates of these two LS174T 
variants, but the subline that strongly expressed Reg IV grew in aggregates on the cultivation 
plates, whereas the variant that expressed only a low level of Reg IV grew in monolayers (K. 
Heiskala, unpublished observations; Fig. 9). The precise characterization of these two 
sublines is still ongoing, but the strongly Reg IV expressing cell line tends to express higher 
levels of other intestinal differentiation markers, as well, suggesting an association with a 
specific differentiated phenotype rather than with growth rate per se (K. Heiskala, 
unpublished observations). These observations are in line with the fact that only about 30% of 
colorectal cancers are Reg IV positive, i.e. Reg IV is not essential for the growth of the tumor 
or the cells, but other growth-promoting mechanisms are readily recruited. On the other hand, 
Reg IV expression has been associated with mucinous type of colon cancer (XH Li et al., 
2010), intestinal or neuroendocrine type of gastric cancer (Oue et al., 2005, Yamagishi et al., 
2009) and the ‘intestinal’ pathway of intraductal papillary mucinous neoplasms of the 
pancreas (Nakata et al., 2009). The above findings suggest that Reg IV might be more clearly 
associated with a specific phenotype of cancer than with a certain stage or prognosis. 
 
 
Figure 9. A photomicrograph of the cell culture plates of the subcloned LS174T cell lines. The 
strongly Reg IV expressing LS174T subclone forms tight aggregates on the plate (A), 
whereas the low Reg IV expressing variant grows in monolayer (B). 
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5.5.4 The role of Reg IV in proliferation and the progression and prognosis of cancer (I, 
III, IV) 
 
The role of Reg IV in cancer progression and in the prognosis of the patients has been 
extensively studied. A correlation between Reg IV expression and the prognosis of NETs or 
PMP was not found in the current study (III, IV, K. Heiskala, unpublished observations). Reg 
IV is expressed in normal gut epithelium; it is upregulated already in early, precancerous 
lesions, and during cancer progression, and the epithelium might even lose Reg IV expression 
(XH Li et al., 2010). Nevertheless, Reg IV sometimes stains positively in the poorly 
differentiated and/or advanced cancers, and it has been considered a marker for poor 
prognosis, too (Numata et al., 2011). Thus, Reg IV seems to have a dual role, firstly, in the 
development of neoplasia, and secondly, in the malignant progression of the advanced 
disease.  
Reg IV is physiologically expressed in the parietal cells of the gastric mucosa (I). Reg 
IV upregulation was described in intestinal metaplasia and in the proliferating margins of 
gastric ulcers in this work (I). Several reports confirm the association of Reg IV with 
intestinal differentiation (Oue et al., 2005) and its upregulation in gastric cancer (Mitani et al., 
2007, Miyagawa et al., Oue et al., 2004 and 2005). Moon et al. (2012) and Tao et al. (2011) 
report that Reg IV expression in gastric cancer correlated positively with poor prognosis, and 
Mitani et al. (2007) report that Reg IV expression correlated with resistance to 5-fluorouracil 
treatment in gastric cancer patients. Suh et al. (2011), however, found Reg IV expression to 
correlate with a better survival in gastric cancer. Zheng et al. (2010) reported no difference in 
the survival rates of 372 gastric carcinoma patients regarding Reg IV expression, and, 
similarly, Yamagishi et al. (2009) did not find any correlation between Reg IV expression and 
the prognosis of gastric cancer.  
In the normal intestine, Reg IV is expressed in neuroendocrine cells and weakly in 
colonic goblet cells (I). The present study (I), as well as Hartupee et al. (2001), Nanakin et al. 
(2006), and Granlund et al. (2011) have described Reg IV upregulation in inflammatory 
bowel diseases. Glebov et al. (2006) have shown that Reg IV is upregulated in normal-
appearing gut epithelium that is in danger of developing an adenoma. Zhang et al. (2003) and 
Lü et al. (2003) have reported strong Reg IV expression in colonic adenomas. Violette et al. 
(2003) first reported strong Reg IV expression in colorectal cancer (CRC). Also in the case of 
CRC, the reports of the role of Reg IV for the prognosis are controversial. Kobunai et al. 
(2011) reported that colorectal cell lines with high Reg IV expression are less sensitive to 
radiation than those with low Reg IV expression. Bishnupuri et al. (2010) reported that 
downregulation of Reg IV expression in CRC cells lines sensitized them to radiation-induced 
apoptosis. Numata et al. (2011) and Oue et al. (2007) found Reg IV expression in colorectal 
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cancer to correlate with poor prognosis. XH Li et al. (2010) examined a colorectal cancer 
series of 320 specimens; they did not find any correlation with Reg IV expression and 
cumulative survival. Zheng et al. (2011) studied the expression of all Reg proteins in 
colorectal cancer, and observed Reg IV more frequently in the adjacent non-neoplastic 
mucosa than in the CRC. Furthermore, although there was a correlation between the 
expression of the other four family members, Reg IV expression did not correlate with the 
others (Zheng et al., 2011). 
In normal pancreas, Reg IV expression was barely detectable (III). Reg IV was, 
however, reported in the sera of pancreatitis patients (Takayama et al., 2010), and it is 
overexpressed in an experimental mouse model of acute pancreatitis (Hu et al., 2011). During 
inflammation, Reg IV expression was induced in both endocrine and exocrine pancreas, and 
Reg IV was reported to protect acinar cells from necrosis by enhancing Bcl-2 and Bcl-xL 
expression via activation of the EGFR/Akt signaling pathway (Hu et al., 2011). Nakata et al. 
(2009) report that Reg IV is overexpressed also in the intestinal type of intraductal papillary 
mucinous neoplasms of the pancreas (IPMN). Reg IV gene copy number has been reported to 
be elevated in late precancerous pancreatic intraductal lesions (PanIN3) and in pancreatic 
cancer cells (Legoffic et al., 2009). Takehara et al. (2006) and Takayama et al. (2010) have 
shown Reg IV expression in pancreatic ductal adenocarcinoma and elevated levels of Reg IV 
protein in the serum of patients with pancreatic cancer, thus proposing it as a novel marker of 
the disease. In pancreatic cancer, Reg IV expression is reported to be under the control of 
glioma-associated oncogene homolog 1 (GLI1), a transcription factor in the Hedgehog 
signaling pathway (Wang et al., 2011). Eguchi et al. (2009) have proposed Reg IV as a 
predictive biomarker for the response of pancreatic cancer patients to preoperative 
chemoradiotherapy, suggesting that Reg IV overexpression was associated with a poor 
response to preoperative treatments and to a poor prognosis.  
Thus, in cancers of the stomach, colorectum, and pancreas, Reg IV expression is 
reported as an early event in the progression of the disease. Reports on its role in the 
progression and in the prognosis of these cancers are more controversial. According to several 
reports, Reg IV seems to induce tumor growth and to inhibit apoptosis and/or necrosis of the 
cells, but it has not proven to be an incontestable indicator of either poor or favorable 
prognosis. In this study, no correlation was found with prognosis in mucinous ovarian cancers 
or in colon cancers (K. Heiskala, unpublished observations). 
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6. Conclusions and future prospects 
 
Reg IV is the only member of the Reg protein group IV. The genomic localization of Reg IV 
is on chromosome 1 (1p12-13.1), while the other human Reg protein genes are clustered on 
chromosome 2 (2p12). The slight structural differences between Reg IV and Reg I/Reg III 
genes suggest that Reg IV represents an early duplication of the ancestor Reg gene. The exon-
intron number and arrangement of Reg IV is similar to that of the other human Reg genes, but 
the introns are larger. The primary structure of the Reg IV protein is 38-39% identical/similar 
to that of the other human Reg proteins, and the functionally important six cystein residues 
and the C-type lectin domain are conserved. There are, however, major differences in the 
amino acid sequence of Reg IV as compared to the other human Reg proteins. Based on the 
early genetic separation and the small structural differences, the protein encoded by Reg IV 
may to have acquired functions that differ from those of the other Reg family proteins. (I) 
Reg IV is primarily expressed in the GI-tract (I). It is expressed in the neuroendocrine 
cells of the intestines (enteroendocrine cells, EEC), and it co-expresses with serotonin, and 
partially also with other markers. Importantly, Reg IV co-expresses with somatostatin and 
ghrelin only in the colon and appendix, but not in the small intestine, suggesting different 
roles for Reg IV and the EECs in different parts of the gut (II). Reg IV expression is 
upregulated in proliferating gut epithelium and in mucinous and endocrine neoplasms. Two 
different expression patterns of Reg IV exist: a perinuclear strong staining, the “endocrine” 
type, and a cytoplasmic, more diffuse, “mucinous” type (I, III, IV).  
The expression of Reg IV in the GI-tract is associated with three modalities: 
regeneration, premalignant and or malignant transformation of the intestinal mucosa, and 
intestinal or neuroendocrine phenotype (I, III, IV). In neoplasia, however, Reg IV expression 
is not limited to the neoplasms of the GI tract, but also other mucinous or endocrine cancers 
may express the protein (IV). Reg IV is suggested to be a potential early marker for gastric, 
pancreatic, and colorectal cancer. It has also been suggested to have a role in predicting the 
prognosis of gastric, pancreatic, colorectal, and prostate cancers, but further studies are 
needed to clarify its role in these diseases.  
The dual role of Reg IV in normal and malignant gut epithelium still remains 
enigmatic. Its two different expression patterns, the endocrine and the mucinous type, and the 
association with a different set of proteins in the EECs of the small intestine and colon 
suggest that the regulation of Reg IV expression is highly complex, and seems to support the 
possible involvement of different splice variants with different expression patterns and 
functions. 
Reg IV is a secreted protein, whose mechanism of action and putative receptor have 
not yet been characterized. As a sugar moieties binding lectin, it may have a role as a 
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microbial antigen-recognizing molecule. As a link to the innate immunity, Reg IV could 
hence participate in the modulation of the stromal surrounding of epithelial cells and in 
malignancies, the tumor microenvironment. 
This work has characterized the structure and expression patterns of the novel protein 
Reg IV, and demonstrated its role in neuroendocrine tumor diagnostics. Further investigation 
of its mechanism of action and association with growth and transformation signaling 
pathways, as well as innate immunity, will enhance its value as a diagnostic and predictive 
marker, and clarify its potential as a target for therapeutic intervention. 
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